[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fxDEHjzwdcC-bxVUgKASnT6QQS5l-WkiCCKixtY8kNog":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"Teva Branded Pharmaceutical Products R&D, Inc.",[4],208,false,0,92,65970,7,[13,16,19,22,25,27,30,32],{"name":14,"count":15},"Asthma",42,{"name":17,"count":18},"Parkinson's Disease",12,{"name":20,"count":21},"Relapsing Remitting Multiple Sclerosis",9,{"name":23,"count":24},"Migraine",8,{"name":26,"count":11},"Multiple Sclerosis",{"name":28,"count":29},"Pharmacokinetics",5,{"name":31,"count":29},"Eosinophilic Asthma",{"name":33,"count":34},"Solid Tumors",4,[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,150,246,299,341,386,431,471,501,537,556,574,599,617,642,660,678,696,714,738,756,774,902,979,1046,1099,1161,1210,1240,1286,1325,1364,1415,1460,1504,1536,1558,1590,1612,1647,1669,1696,1731,1766,1793,1820,1838,1861,1887,1905,1923,1945,1968,1986,2009,2027,2050,2068,2086,2104,2122,2140,2158,2176,2194,2218,2243,2261,2286,2304,2330,2348,2366,2384,2408,2426,2444,2462,2487,2505,2523,2541,2559,2577,2595,2619,2646,2664,2682,2700,2724,2750,2836,2889,2932,2954,2990,3012,3045,3080,3122,3154,3179,3197,3219,3246,3264,3282,3305,3328,3346,3364,3390,3408,3426,3444,3462,3486,3504,3527,3549,3567,3591,3609,3627,3645,3667,3685,3703,3721,3739,3757,3775,3793,3817,3841,3859,3877,3899,3936,3959,3982,4000,4022,4046,4064,4082,4106,4124,4148,4166,4190,4208,4226,4244,4262,4280,4304,4322,4343,4361,4379,4397,4417,4442,4460,4483,4501,4525,4543,4564,4587,4610,4628,4653,4671,4689,4711,4735,4753,4771,4789,4807,4965,5045,5092,5118,5136,5154],{"intervention":45,"totalTrials":21,"cells":46},"Reslizumab",{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":51,"PHASE3":53,"PHASE4":137,"NA":148},{"trials":48,"activeCount":8},[],{"trials":50,"activeCount":8},[],{"trials":52,"activeCount":8},[],{"trials":54,"activeCount":8},[55,67,78,88,101,110,119,128],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":65},"NCT03052725","A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma","TERMINATED",[40],"2018-02-22","2017-03-10",391,[64],"Eosinophils, Asthma",[66],"reslizumab",{"nctId":68,"briefTitle":69,"status":70,"phases":71,"primaryCompletion":72,"completion":73,"start":74,"enrollment":75,"conditions":76,"interventions":77},"NCT02452190","Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils","COMPLETED",[40],"2017-12-04","2018-01-31","2015-09-28",468,[14],[45],{"nctId":79,"briefTitle":80,"status":70,"phases":81,"primaryCompletion":82,"completion":83,"start":84,"enrollment":85,"conditions":86,"interventions":87},"NCT01287039","A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg\u002Fkg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma",[40],"2013-12","2014-03","2011-04",489,[31],[45],{"nctId":89,"briefTitle":90,"status":70,"phases":91,"primaryCompletion":92,"completion":72,"start":93,"enrollment":94,"conditions":95,"interventions":98},"NCT02501629","An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils",[40],"2017-06-19","2015-09-29",177,[14,96,97],"Elevated Blood Eosinophils","Oral Corticosteroid Dependence",[45,99,100],"Non-Oral Corticosteroid (non-OCS) Asthma Medication","Oral Corticosteroid",{"nctId":102,"briefTitle":103,"status":70,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT01285323","A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma",[40],"2014-04","2011-03",464,[31],[45],{"nctId":111,"briefTitle":112,"status":58,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":118},"NCT01290887","Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg\u002Fkg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma",[40],"2015-01","2011-06",1052,[31],[45],{"nctId":120,"briefTitle":121,"status":70,"phases":122,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":127},"NCT01508936","Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma",[40],"2013-08","2012-02",511,[31],[45],{"nctId":129,"briefTitle":130,"status":70,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":136},"NCT01270464","A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg\u002Fkg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma",[40],"2013-09","2011-02",315,[31],[45],{"trials":138,"activeCount":8},[139],{"nctId":140,"briefTitle":141,"status":58,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":29,"conditions":145,"interventions":146},"NCT02937168","An Imaging Study Using PET\u002FCT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation",[41],"2017-05-24","2017-05-08",[14],[45,147],"Fludeoxyglucose F 18",{"trials":149,"activeCount":8},[],{"intervention":151,"totalTrials":24,"cells":152},"Glatiramer Acetate",{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":214,"NA":244},{"trials":154,"activeCount":8},[],{"trials":156,"activeCount":8},[],{"trials":158,"activeCount":8},[],{"trials":160,"activeCount":8},[161,172,182,193,203],{"nctId":162,"briefTitle":163,"status":58,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},"NCT01578785","An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg\u002F0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)",[40],"2012-10","2012-11","2012-03",178,[170],"Relapsing-Remitting Multiple Sclerosis",[151],{"nctId":173,"briefTitle":174,"status":70,"phases":175,"primaryCompletion":176,"completion":133,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT00856635","A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)",[40],"2010-12","2009-02",44,[180],"Optic Neuritis",[151],{"nctId":183,"briefTitle":184,"status":70,"phases":185,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":191},"NCT00947752","Safety of New Formulation of Glatiramer Acetate",[40],"2009-09","2009-11","2009-07",147,[20],[151,192],"Experimental Glatiramer Acetate",{"nctId":194,"briefTitle":195,"status":70,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":202},"NCT00666224","Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome",[40],"2007-10","2010-06","2004-01",481,[26],[151,151],{"nctId":204,"briefTitle":205,"status":70,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":212},"NCT01067521","A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo",[40],"2012-05-08","2017-05-12","2010-06-22",1404,[20],[213],"Glatiramer acetate",{"trials":215,"activeCount":8},[216,226,236],{"nctId":217,"briefTitle":218,"status":58,"phases":219,"primaryCompletion":197,"completion":197,"start":220,"enrollment":221,"conditions":222,"interventions":223},"NCT00202995","Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS",[41],"2004-07",91,[20],[151,224,225],"Betaseron","Rebif",{"nctId":227,"briefTitle":228,"status":58,"phases":229,"primaryCompletion":230,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":234},"NCT00203047","Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate",[41],"2009-05","2005-01",414,[20],[151,235],"Prednisone",{"nctId":237,"briefTitle":238,"status":70,"phases":239,"primaryCompletion":240,"completion":240,"start":241,"enrollment":6,"conditions":242,"interventions":243},"NCT00203021","Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness",[41],"2018-02-28","1994-03-26",[170],[213],{"trials":245,"activeCount":8},[],{"intervention":247,"totalTrials":248,"cells":249},"Fluticasone propionate\u002Fsalmeterol",3,{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":266,"PHASE3":268,"PHASE4":282,"NA":297},{"trials":251,"activeCount":8},[],{"trials":253,"activeCount":8},[254],{"nctId":255,"briefTitle":256,"status":70,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":263},"NCT02680561","A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma",[38],"2016-06","2016-08","2016-04",20,[14],[264,265,247],"Fluticasone Propionate MDPI","Fluticasone Propionate\u002FSalmeterol MDPI",{"trials":267,"activeCount":8},[],{"trials":269,"activeCount":8},[270],{"nctId":271,"briefTitle":272,"status":70,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":279},"NCT02980133","Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate\u002FSalmeterol Multidose Dry Powder Inhaler",[40],"2019-04-07","2019-04-13","2016-12-28",841,[14],[280,281],"Fluticasone Propionate","Fluticasone Propionate\u002FSalmeterol",{"trials":283,"activeCount":8},[284],{"nctId":285,"briefTitle":286,"status":70,"phases":287,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":293},"NCT04677959","A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma",[41],"2022-03-04","2022-03-10","2021-02-16",427,[14],[247,294,295,296],"Albuterol","Standard of Care Asthma Medication","Standard of Care Rescue Medication",{"trials":298,"activeCount":8},[],{"intervention":300,"totalTrials":248,"cells":301},"Rasagiline",{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":315,"PHASE3":328,"PHASE4":330,"NA":339},{"trials":303,"activeCount":8},[],{"trials":305,"activeCount":8},[306],{"nctId":307,"briefTitle":308,"status":70,"phases":309,"primaryCompletion":132,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":314},"NCT01879748","A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline",[38],"2013-11","2013-06",64,[17],[300],{"trials":316,"activeCount":8},[317],{"nctId":318,"briefTitle":319,"status":70,"phases":320,"primaryCompletion":321,"start":322,"enrollment":323,"conditions":324,"interventions":327},"NCT00104273","Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)",[39],"2007-03","2004-08",376,[325,326],"Dementia","Alzheimer's Disease",[300],{"trials":329,"activeCount":8},[],{"trials":331,"activeCount":8},[332],{"nctId":333,"briefTitle":334,"status":70,"phases":335,"primaryCompletion":114,"completion":114,"start":166,"enrollment":336,"conditions":337,"interventions":338},"NCT01723228","Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease",[41],170,[17],[300],{"trials":340,"activeCount":8},[],{"intervention":235,"totalTrials":248,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":378,"NA":384},{"trials":344,"activeCount":8},[],{"trials":346,"activeCount":8},[],{"trials":348,"activeCount":8},[],{"trials":350,"activeCount":8},[351,368],{"nctId":352,"briefTitle":353,"status":70,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":361},"NCT00877006","Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study",[40],"2012-03-31","2009-04-30",447,[359,360],"Non-Hodgkin's Lymphoma","Mantle Cell Lymphoma",[362,363,364,365,366,367],"bendamustine","rituximab","vincristine","prednisone","cyclophosphamide","doxorubicin",{"nctId":369,"briefTitle":370,"status":70,"phases":371,"primaryCompletion":372,"completion":372,"start":198,"enrollment":373,"conditions":374,"interventions":376},"NCT01133626","Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)",[40],"2010-09",107,[375],"Perennial Allergic Rhinitis",[235,377],"Beclomethasone dipropionate",{"trials":379,"activeCount":8},[380],{"nctId":227,"briefTitle":228,"status":58,"phases":381,"primaryCompletion":230,"completion":230,"start":231,"enrollment":232,"conditions":382,"interventions":383},[41],[20],[151,235],{"trials":385,"activeCount":8},[],{"intervention":387,"totalTrials":248,"cells":388},"Flovent Diskus",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":415,"PHASE4":417,"NA":429},{"trials":390,"activeCount":8},[],{"trials":392,"activeCount":8},[],{"trials":394,"activeCount":8},[395,406],{"nctId":396,"briefTitle":397,"status":70,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":403},"NCT01479621","A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids",[39],"2013-07","2012-01",909,[14],[404,387,405],"Fp MDPI","albuterol\u002Fsalbutamol",{"nctId":407,"briefTitle":408,"status":70,"phases":409,"primaryCompletion":399,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":414},"NCT01576718","A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications",[39],"2013-10","2012-04",889,[14],[404,387,405],{"trials":416,"activeCount":8},[],{"trials":418,"activeCount":8},[419],{"nctId":420,"briefTitle":421,"status":58,"phases":422,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":427},"NCT00071552","Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents\u002FAdult Patients",[41],"2006-07-31","2004-01-31",49,[14],[428,387],"Qvar",{"trials":430,"activeCount":8},[],{"intervention":432,"totalTrials":433,"cells":434},"Mycophenolate Mofetil",2,{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":454,"PHASE4":456,"NA":469},{"trials":436,"activeCount":8},[],{"trials":438,"activeCount":8},[],{"trials":440,"activeCount":8},[441],{"nctId":442,"briefTitle":443,"status":70,"phases":444,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":450},"NCT01085097","A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis",[39],"2012-10-24","2010-09-01",46,[449],"Lupus Nephritis",[451,432,452,453],"Laquinimod","Prednisolone\u002FPrednisone","Methylprednisolone",{"trials":455,"activeCount":8},[],{"trials":457,"activeCount":8},[458],{"nctId":459,"briefTitle":460,"status":58,"phases":461,"primaryCompletion":462,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":467},"NCT00991510","Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients",[41],"2010-10","2009-08",43,[466],"Stable Renal Transplant Recipients",[468,468],"mycophenolate mofetil",{"trials":470,"activeCount":8},[],{"intervention":472,"totalTrials":433,"cells":473},"QVAR",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":499},{"trials":475,"activeCount":8},[],{"trials":477,"activeCount":8},[],{"trials":479,"activeCount":8},[],{"trials":481,"activeCount":8},[],{"trials":483,"activeCount":8},[484,495],{"nctId":485,"briefTitle":486,"status":70,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":492},"NCT00250341","Non-invasive Measures of Distal Lung Disease in Asthmatics",[41],"2007-09-30","2005-09-30",34,[14],[472,493,494],"Advair","Servent Diskus",{"nctId":420,"briefTitle":421,"status":58,"phases":496,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":497,"interventions":498},[41],[14],[428,387],{"trials":500,"activeCount":8},[],{"intervention":502,"totalTrials":433,"cells":503},"Glatiramer acetate with placebo",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":521,"PHASE4":523,"NA":535},{"trials":505,"activeCount":8},[],{"trials":507,"activeCount":8},[],{"trials":509,"activeCount":8},[510],{"nctId":511,"briefTitle":512,"status":70,"phases":513,"primaryCompletion":514,"completion":515,"start":516,"enrollment":178,"conditions":517,"interventions":519},"NCT00203112","Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline",[39],"2006-06","2006-07","2004-06",[518],"Relapse Remitting Multiple Sclerosis",[520,502],"glatiramer acetate with minocycline",{"trials":522,"activeCount":8},[],{"trials":524,"activeCount":8},[525],{"nctId":526,"briefTitle":527,"status":70,"phases":528,"primaryCompletion":514,"completion":515,"start":529,"enrollment":530,"conditions":531,"interventions":532},"NCT00240032","A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.",[41],"2004-10",80,[26],[533,534],"glatiramer acetate injection with oral cetirizine hydrochloride","glatiramer acetate with placebo",{"trials":536,"activeCount":8},[],{"intervention":295,"totalTrials":538,"cells":539},1,{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":548,"NA":554},{"trials":541,"activeCount":8},[],{"trials":543,"activeCount":8},[],{"trials":545,"activeCount":8},[],{"trials":547,"activeCount":8},[],{"trials":549,"activeCount":8},[550],{"nctId":285,"briefTitle":286,"status":70,"phases":551,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":552,"interventions":553},[41],[14],[247,294,295,296],{"trials":555,"activeCount":8},[],{"intervention":296,"totalTrials":538,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":572},{"trials":559,"activeCount":8},[],{"trials":561,"activeCount":8},[],{"trials":563,"activeCount":8},[],{"trials":565,"activeCount":8},[],{"trials":567,"activeCount":8},[568],{"nctId":285,"briefTitle":286,"status":70,"phases":569,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":570,"interventions":571},[41],[14],[247,294,295,296],{"trials":573,"activeCount":8},[],{"intervention":575,"totalTrials":538,"cells":576},"Albuterol eMDPI DS",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":585,"NA":597},{"trials":578,"activeCount":8},[],{"trials":580,"activeCount":8},[],{"trials":582,"activeCount":8},[],{"trials":584,"activeCount":8},[],{"trials":586,"activeCount":8},[587],{"nctId":588,"briefTitle":589,"status":70,"phases":590,"primaryCompletion":591,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":595},"NCT03890666","A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma",[41],"2021-10-04","2020-10-26",333,[14],[575,596],"albuterol",{"trials":598,"activeCount":8},[],{"intervention":147,"totalTrials":538,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":615},{"trials":602,"activeCount":8},[],{"trials":604,"activeCount":8},[],{"trials":606,"activeCount":8},[],{"trials":608,"activeCount":8},[],{"trials":610,"activeCount":8},[611],{"nctId":140,"briefTitle":141,"status":58,"phases":612,"primaryCompletion":143,"completion":143,"start":144,"enrollment":29,"conditions":613,"interventions":614},[41],[14],[45,147],{"trials":616,"activeCount":8},[],{"intervention":618,"totalTrials":538,"cells":619},"Copaxone®",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":628,"NA":640},{"trials":621,"activeCount":8},[],{"trials":623,"activeCount":8},[],{"trials":625,"activeCount":8},[],{"trials":627,"activeCount":8},[],{"trials":629,"activeCount":8},[630],{"nctId":631,"briefTitle":632,"status":70,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":639},"NCT02499900","Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®",[41],"2017-01-10","2017-06-02","2015-08-10",861,[26],[618],{"trials":641,"activeCount":8},[],{"intervention":224,"totalTrials":538,"cells":643},{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":650,"PHASE4":652,"NA":658},{"trials":645,"activeCount":8},[],{"trials":647,"activeCount":8},[],{"trials":649,"activeCount":8},[],{"trials":651,"activeCount":8},[],{"trials":653,"activeCount":8},[654],{"nctId":217,"briefTitle":218,"status":58,"phases":655,"primaryCompletion":197,"completion":197,"start":220,"enrollment":221,"conditions":656,"interventions":657},[41],[20],[151,224,225],{"trials":659,"activeCount":8},[],{"intervention":225,"totalTrials":538,"cells":661},{"EARLY_PHASE1":662,"PHASE1":664,"PHASE2":666,"PHASE3":668,"PHASE4":670,"NA":676},{"trials":663,"activeCount":8},[],{"trials":665,"activeCount":8},[],{"trials":667,"activeCount":8},[],{"trials":669,"activeCount":8},[],{"trials":671,"activeCount":8},[672],{"nctId":217,"briefTitle":218,"status":58,"phases":673,"primaryCompletion":197,"completion":197,"start":220,"enrollment":221,"conditions":674,"interventions":675},[41],[20],[151,224,225],{"trials":677,"activeCount":8},[],{"intervention":493,"totalTrials":538,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":694},{"trials":681,"activeCount":8},[],{"trials":683,"activeCount":8},[],{"trials":685,"activeCount":8},[],{"trials":687,"activeCount":8},[],{"trials":689,"activeCount":8},[690],{"nctId":485,"briefTitle":486,"status":70,"phases":691,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":692,"interventions":693},[41],[14],[472,493,494],{"trials":695,"activeCount":8},[],{"intervention":494,"totalTrials":538,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":712},{"trials":699,"activeCount":8},[],{"trials":701,"activeCount":8},[],{"trials":703,"activeCount":8},[],{"trials":705,"activeCount":8},[],{"trials":707,"activeCount":8},[708],{"nctId":485,"briefTitle":486,"status":70,"phases":709,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":710,"interventions":711},[41],[14],[472,493,494],{"trials":713,"activeCount":8},[],{"intervention":715,"totalTrials":538,"cells":716},"Albuterol-HFA-MDI",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":736},{"trials":718,"activeCount":8},[],{"trials":720,"activeCount":8},[],{"trials":722,"activeCount":8},[],{"trials":724,"activeCount":8},[],{"trials":726,"activeCount":8},[727],{"nctId":728,"briefTitle":729,"status":70,"phases":730,"primaryCompletion":731,"completion":731,"start":732,"enrollment":425,"conditions":733,"interventions":734},"NCT00530062","Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma",[41],"2008-10-24","2007-07-25",[14],[715,735],"Albuterol-HFA-BAI",{"trials":737,"activeCount":8},[],{"intervention":735,"totalTrials":538,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":754},{"trials":741,"activeCount":8},[],{"trials":743,"activeCount":8},[],{"trials":745,"activeCount":8},[],{"trials":747,"activeCount":8},[],{"trials":749,"activeCount":8},[750],{"nctId":728,"briefTitle":729,"status":70,"phases":751,"primaryCompletion":731,"completion":731,"start":732,"enrollment":425,"conditions":752,"interventions":753},[41],[14],[715,735],{"trials":755,"activeCount":8},[],{"intervention":533,"totalTrials":538,"cells":757},{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":764,"PHASE4":766,"NA":772},{"trials":759,"activeCount":8},[],{"trials":761,"activeCount":8},[],{"trials":763,"activeCount":8},[],{"trials":765,"activeCount":8},[],{"trials":767,"activeCount":8},[768],{"nctId":526,"briefTitle":527,"status":70,"phases":769,"primaryCompletion":514,"completion":515,"start":529,"enrollment":530,"conditions":770,"interventions":771},[41],[26],[533,534],{"trials":773,"activeCount":8},[],{"intervention":451,"totalTrials":18,"cells":775},{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":792,"PHASE3":840,"PHASE4":898,"NA":900},{"trials":777,"activeCount":8},[],{"trials":779,"activeCount":8},[780],{"nctId":781,"briefTitle":782,"status":70,"phases":783,"primaryCompletion":784,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":790},"NCT02085863","A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together",[38],"2014-09","2014-11","2014-02",40,[28,789],"Pharmacodynamics",[791],"laquinimod",{"trials":793,"activeCount":8},[794,804,815,825,829],{"nctId":795,"briefTitle":796,"status":70,"phases":797,"primaryCompletion":798,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":803},"NCT01085084","A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis",[39],"2012-11-12","2010-10-04",82,[802],"Lupus Arthritis",[451],{"nctId":805,"briefTitle":806,"status":70,"phases":807,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":814},"NCT00737932","Laquinimod Phase IIa Study in Active Crohn's Disease",[39],"2011-11","2011-12","2010-05",180,[813],"Crohn's Disease",[451],{"nctId":816,"briefTitle":817,"status":70,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":824},"NCT02215616","A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod",[39],"2018-06-19","2014-10-28",352,[823],"Huntington's Disease",[451],{"nctId":442,"briefTitle":443,"status":70,"phases":826,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":827,"interventions":828},[39],[449],[451,432,452,453],{"nctId":830,"briefTitle":831,"status":70,"phases":832,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":839},"NCT02284568","A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg\u002FDay or 1.5mg\u002FDay (Experimental Drug) as Compared to Placebo",[39],"2017-05-04","2017-10-01","2015-01-12",374,[838],"Primary Progressive Multiple Sclerosis",[451],{"trials":841,"activeCount":8},[842,851,860,870,880,889],{"nctId":843,"briefTitle":844,"status":845,"phases":846,"primaryCompletion":83,"completion":83,"start":847,"enrollment":8,"conditions":848,"interventions":849},"NCT01975298","A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)","WITHDRAWN",[40],"2014-01",[20],[451,850],"Avonex®",{"nctId":852,"briefTitle":853,"status":70,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":857,"conditions":858,"interventions":859},"NCT00509145","Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)",[40],"2010-11-08","2007-11-13",1106,[26],[451],{"nctId":861,"briefTitle":862,"status":58,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":869},"NCT01047319","A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis",[40],"2017-06-30","2010-05-27",1047,[868],"Relapsing Multiple Sclerosis",[451],{"nctId":871,"briefTitle":872,"status":70,"phases":873,"primaryCompletion":874,"completion":875,"start":876,"enrollment":877,"conditions":878,"interventions":879},"NCT01707992","The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",[40],"2015-04-13","2017-07-04","2013-02-20",2199,[26],[451],{"nctId":881,"briefTitle":882,"status":70,"phases":883,"primaryCompletion":884,"completion":884,"start":885,"enrollment":886,"conditions":887,"interventions":888},"NCT00605215","BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)",[40],"2011-06-10","2008-04-24",1331,[26],[451,850],{"nctId":890,"briefTitle":891,"status":58,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":897},"NCT00988052","A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course",[40],"2017-07-01","2009-11-10",839,[868],[451],{"trials":899,"activeCount":8},[],{"trials":901,"activeCount":8},[],{"intervention":377,"totalTrials":11,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":975,"NA":977},{"trials":905,"activeCount":8},[],{"trials":907,"activeCount":8},[],{"trials":909,"activeCount":8},[],{"trials":911,"activeCount":8},[912,922,931,935,945,956,965],{"nctId":913,"briefTitle":914,"status":70,"phases":915,"primaryCompletion":916,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":920},"NCT00109668","Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids",[40],"2006-09-30","2004-07-31",415,[14],[921],"beclomethasone dipropionate",{"nctId":923,"briefTitle":924,"status":70,"phases":925,"primaryCompletion":785,"completion":926,"start":82,"enrollment":927,"conditions":928,"interventions":929},"NCT02031640","A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma",[40],"2014-12",1113,[14],[377,930],"Albuterol\u002Fsalbutamol",{"nctId":369,"briefTitle":370,"status":70,"phases":932,"primaryCompletion":372,"completion":372,"start":198,"enrollment":373,"conditions":933,"interventions":934},[40],[375],[235,377],{"nctId":936,"briefTitle":937,"status":70,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":944},"NCT00988247","Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis",[40],"2011-02-28","2009-10-31",529,[943],"Rhinitis, Allergic, Perennial",[377],{"nctId":946,"briefTitle":947,"status":70,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":952,"interventions":955},"NCT01024608","Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)",[40],"2010-02-28","2009-12-31",340,[953,954],"Seasonal Allergic Rhinitis","Hay Fever",[377],{"nctId":957,"briefTitle":958,"status":70,"phases":959,"primaryCompletion":960,"completion":960,"start":961,"enrollment":962,"conditions":963,"interventions":964},"NCT00094016","Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children",[40],"2006-06-30","2004-10-31",440,[14],[921],{"nctId":966,"briefTitle":967,"status":70,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":972,"interventions":973},"NCT02139644","Study of Fluticasone Propionate MDPI Compared With Fluticasone\u002FSalmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma",[40],"2015-09","2014-06",787,[14],[974,404,405,377],"FS MDPI",{"trials":976,"activeCount":8},[],{"trials":978,"activeCount":8},[],{"intervention":404,"totalTrials":11,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":996,"PHASE3":1015,"PHASE4":1042,"NA":1044},{"trials":982,"activeCount":8},[],{"trials":984,"activeCount":8},[985],{"nctId":986,"briefTitle":987,"status":70,"phases":988,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":994},"NCT06290102","Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old",[38],"2024-10-01","2024-10-07","2024-05-16",30,[14],[995,404],"TEV-56248",{"trials":997,"activeCount":8},[998,1007,1011],{"nctId":999,"briefTitle":1000,"status":70,"phases":1001,"primaryCompletion":311,"completion":311,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1005},"NCT01772368","Dose Ranging Study of the Salmeterol Component of Fluticasone \u002FSalmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects",[39],"2013-01",72,[14],[404,974,1006,294],"Advair Diskus",{"nctId":396,"briefTitle":397,"status":70,"phases":1008,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":1009,"interventions":1010},[39],[14],[404,387,405],{"nctId":407,"briefTitle":408,"status":70,"phases":1012,"primaryCompletion":399,"completion":410,"start":411,"enrollment":412,"conditions":1013,"interventions":1014},[39],[14],[404,387,405],{"trials":1016,"activeCount":8},[1017,1030,1038],{"nctId":1018,"briefTitle":1019,"status":70,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1026},"NCT02175771","Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate\u002FSalmeterol (FS) MDPI in Patients With Persistent Asthma",[40],"2015-07","2014-07",758,[1025],"Persistent Asthma",[404,974,1027,1028,1029],"FLOVENT HFA","ADVAIR DISKUS","albuterol\u002Fsalbutamol HFA",{"nctId":1031,"briefTitle":1032,"status":70,"phases":1033,"primaryCompletion":969,"completion":969,"start":970,"enrollment":1034,"conditions":1035,"interventions":1036},"NCT02141854","Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma",[40],882,[14],[974,404,1037],"Albuterol\u002Fsalmeterol HFA MDI",{"nctId":966,"briefTitle":967,"status":70,"phases":1039,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":1040,"interventions":1041},[40],[14],[974,404,405,377],{"trials":1043,"activeCount":8},[],{"trials":1045,"activeCount":8},[],{"intervention":405,"totalTrials":1047,"cells":1048},6,{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1063,"PHASE4":1095,"NA":1097},{"trials":1050,"activeCount":8},[],{"trials":1052,"activeCount":8},[],{"trials":1054,"activeCount":8},[1055,1059],{"nctId":396,"briefTitle":397,"status":70,"phases":1056,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":1057,"interventions":1058},[39],[14],[404,387,405],{"nctId":407,"briefTitle":408,"status":70,"phases":1060,"primaryCompletion":399,"completion":410,"start":411,"enrollment":412,"conditions":1061,"interventions":1062},[39],[14],[404,387,405],{"trials":1064,"activeCount":8},[1065,1075,1087,1091],{"nctId":1066,"briefTitle":1067,"status":70,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT02040779","A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg\u002FDay) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma",[40],"2014-12-24","2013-12-26",273,[1025],[1074,405],"Beclomethasone dipropionate breath-actuated inhaler",{"nctId":1076,"briefTitle":1077,"status":70,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1083},"NCT02513160","Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma",[40],"2016-03-31","2015-09-30",713,[1025],[1084,1085,405,1086],"Beclomethasone Dipropionate 640","Beclomethasone dipropionate via 320 mcg BAI","Beclomethasone dipropionate via 320 mcg MDI",{"nctId":923,"briefTitle":924,"status":70,"phases":1088,"primaryCompletion":785,"completion":926,"start":82,"enrollment":927,"conditions":1089,"interventions":1090},[40],[14],[377,930],{"nctId":966,"briefTitle":967,"status":70,"phases":1092,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":1093,"interventions":1094},[40],[14],[974,404,405,377],{"trials":1096,"activeCount":8},[],{"trials":1098,"activeCount":8},[],{"intervention":1100,"totalTrials":29,"cells":1101},"TEV-50717",{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1157,"NA":1159},{"trials":1103,"activeCount":8},[],{"trials":1105,"activeCount":8},[],{"trials":1107,"activeCount":8},[],{"trials":1109,"activeCount":8},[1110,1119,1129,1139,1148],{"nctId":1111,"briefTitle":1112,"status":58,"phases":1113,"primaryCompletion":1114,"completion":1114,"start":1115,"enrollment":178,"conditions":1116,"interventions":1118},"NCT04200352","A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy",[40],"2023-02-14","2020-02-04",[1117],"Cerebral Palsy, Dyskinetic",[1100],{"nctId":1120,"briefTitle":1121,"status":70,"phases":1122,"primaryCompletion":1123,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1128},"NCT03813238","A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents",[40],"2022-07-05","2022-07-21","2019-08-06",63,[1117],[1100],{"nctId":1130,"briefTitle":1131,"status":70,"phases":1132,"primaryCompletion":1133,"completion":1133,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1138},"NCT03452943","Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents",[39,40],"2019-11-12","2018-02-05",119,[1137],"Tourette Syndrome",[1100],{"nctId":1140,"briefTitle":1141,"status":58,"phases":1142,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1147},"NCT03567291","Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents",[40],"2020-05-15","2018-05-25",228,[1137],[1100],{"nctId":1149,"briefTitle":1150,"status":70,"phases":1151,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1156},"NCT03571256","A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)",[40],"2019-12-09","2018-05-31",158,[1137],[1100],{"trials":1158,"activeCount":8},[],{"trials":1160,"activeCount":8},[],{"intervention":1162,"totalTrials":34,"cells":1163},"Hydrocodone ER",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1206,"NA":1208},{"trials":1165,"activeCount":8},[],{"trials":1167,"activeCount":8},[],{"trials":1169,"activeCount":8},[],{"trials":1171,"activeCount":8},[1172,1181,1190,1198],{"nctId":1173,"briefTitle":1174,"status":70,"phases":1175,"primaryCompletion":1176,"completion":1176,"start":462,"enrollment":1177,"conditions":1178,"interventions":1180},"NCT01223365","Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time",[40],"2012-09",330,[1179],"Chronic Pain",[1162],{"nctId":1182,"briefTitle":1183,"status":70,"phases":1184,"primaryCompletion":786,"completion":786,"start":1185,"enrollment":1186,"conditions":1187,"interventions":1189},"NCT01789970","Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain",[40],"2013-03",625,[1188],"Low Back Pain",[1162],{"nctId":1191,"briefTitle":1192,"status":70,"phases":1193,"primaryCompletion":1194,"completion":1194,"start":399,"enrollment":1195,"conditions":1196,"interventions":1197},"NCT01922739","Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets",[40],"2014-08",182,[1188],[1162],{"nctId":1199,"briefTitle":1200,"status":70,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":62,"conditions":1204,"interventions":1205},"NCT01240863","Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time",[40],"2011-08","2010-11",[1179],[1162],{"trials":1207,"activeCount":8},[],{"trials":1209,"activeCount":8},[],{"intervention":974,"totalTrials":34,"cells":1211},{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1222,"PHASE4":1236,"NA":1238},{"trials":1213,"activeCount":8},[],{"trials":1215,"activeCount":8},[],{"trials":1217,"activeCount":8},[1218],{"nctId":999,"briefTitle":1000,"status":70,"phases":1219,"primaryCompletion":311,"completion":311,"start":1002,"enrollment":1003,"conditions":1220,"interventions":1221},[39],[14],[404,974,1006,294],{"trials":1223,"activeCount":8},[1224,1228,1232],{"nctId":1018,"briefTitle":1019,"status":70,"phases":1225,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":1226,"interventions":1227},[40],[1025],[404,974,1027,1028,1029],{"nctId":1031,"briefTitle":1032,"status":70,"phases":1229,"primaryCompletion":969,"completion":969,"start":970,"enrollment":1034,"conditions":1230,"interventions":1231},[40],[14],[974,404,1037],{"nctId":966,"briefTitle":967,"status":70,"phases":1233,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":1234,"interventions":1235},[40],[14],[974,404,405,377],{"trials":1237,"activeCount":8},[],{"trials":1239,"activeCount":8},[],{"intervention":1241,"totalTrials":34,"cells":1242},"Albuterol MDPI",{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1249,"PHASE4":1282,"NA":1284},{"trials":1244,"activeCount":8},[],{"trials":1246,"activeCount":8},[],{"trials":1248,"activeCount":8},[],{"trials":1250,"activeCount":8},[1251,1259,1269,1276],{"nctId":1252,"briefTitle":1253,"status":70,"phases":1254,"primaryCompletion":410,"completion":310,"start":1255,"enrollment":1256,"conditions":1257,"interventions":1258},"NCT01747629","Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics",[40],"2012-12",160,[14],[1241],{"nctId":1260,"briefTitle":1261,"status":70,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1267},"NCT02126839","A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics",[40],"2015-02","2014-05",186,[14],[1241,1268],"ProAir HFA inhaler",{"nctId":1270,"briefTitle":1271,"status":70,"phases":1272,"primaryCompletion":82,"completion":82,"start":165,"enrollment":1273,"conditions":1274,"interventions":1275},"NCT01698320","Safety Study of Albuterol Spiromax® in Subjects With Asthma",[40],364,[14],[1241],{"nctId":1277,"briefTitle":1278,"status":70,"phases":1279,"primaryCompletion":410,"completion":310,"start":1255,"enrollment":1154,"conditions":1280,"interventions":1281},"NCT01424813","A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma",[40],[14],[1241],{"trials":1283,"activeCount":8},[],{"trials":1285,"activeCount":8},[],{"intervention":1287,"totalTrials":248,"cells":1288},"Albuterol Spiromax",{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1303,"PHASE4":1321,"NA":1323},{"trials":1290,"activeCount":8},[],{"trials":1292,"activeCount":8},[],{"trials":1294,"activeCount":8},[1295],{"nctId":1296,"briefTitle":1297,"status":70,"phases":1298,"primaryCompletion":410,"completion":410,"start":399,"enrollment":1299,"conditions":1300,"interventions":1301},"NCT01899144","Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients",[39],61,[14],[1287,1302],"ProAir HFA",{"trials":1304,"activeCount":8},[1305,1312],{"nctId":1306,"briefTitle":1307,"status":58,"phases":1308,"primaryCompletion":176,"completion":176,"start":462,"enrollment":1309,"conditions":1310,"interventions":1311},"NCT01218009","A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing",[40],331,[14],[1287],{"nctId":1313,"briefTitle":1314,"status":70,"phases":1315,"primaryCompletion":1316,"completion":311,"start":1185,"enrollment":1317,"conditions":1318,"interventions":1320},"NCT01791972","Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)",[40],"2013-05",38,[1319],"Exercise-Induced Bronchoconstriction (EIB)",[1287],{"trials":1322,"activeCount":8},[],{"trials":1324,"activeCount":8},[],{"intervention":1326,"totalTrials":248,"cells":1327},"Albuterol Spiromax®",{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1341,"PHASE3":1350,"PHASE4":1360,"NA":1362},{"trials":1329,"activeCount":8},[],{"trials":1331,"activeCount":8},[1332],{"nctId":1333,"briefTitle":1334,"status":70,"phases":1335,"primaryCompletion":123,"completion":410,"start":1336,"enrollment":1337,"conditions":1338,"interventions":1339},"NCT01844401","Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma",[38],"2013-04",15,[14],[1326,1340],"ProAir® HFA",{"trials":1342,"activeCount":8},[1343],{"nctId":1344,"briefTitle":1345,"status":70,"phases":1346,"primaryCompletion":198,"completion":198,"start":1347,"enrollment":1003,"conditions":1348,"interventions":1349},"NCT01058863","A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma",[39],"2010-02",[14],[1326,1340],{"trials":1351,"activeCount":8},[1352],{"nctId":1353,"briefTitle":1354,"status":70,"phases":1355,"primaryCompletion":123,"completion":132,"start":1316,"enrollment":1356,"conditions":1357,"interventions":1359},"NCT01857323","Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)",[40],317,[14,1358],"Chronic Obstructive Pulmonary Disease (COPD)",[1326],{"trials":1361,"activeCount":8},[],{"trials":1363,"activeCount":8},[],{"intervention":1365,"totalTrials":248,"cells":1366},"Pegfilgrastim",{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1373,"PHASE4":1411,"NA":1413},{"trials":1368,"activeCount":8},[],{"trials":1370,"activeCount":8},[],{"trials":1372,"activeCount":8},[],{"trials":1374,"activeCount":8},[1375,1387,1398],{"nctId":1376,"briefTitle":1377,"status":70,"phases":1378,"primaryCompletion":1379,"completion":1379,"start":1380,"enrollment":1381,"conditions":1382,"interventions":1384},"NCT00837265","Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin\u002FDocetaxel",[39,40],"2009-06-26","2008-08-21",334,[1383],"Chemotherapy-induced Neutropenia",[1385,1365,1386],"Balugrastim","Chemotherapy Regimen",{"nctId":1388,"briefTitle":1389,"status":70,"phases":1390,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1395},"NCT01126190","Neugranin in Breast Cancer Participants Receiving Doxorubicin\u002FDocetaxel",[40],"2012-02-29","2010-06-30",381,[1383],[1396,1365,1397],"Neugranin","Chemotherapy",{"nctId":1399,"briefTitle":1400,"status":70,"phases":1401,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":1406,"interventions":1408},"NCT02044276","A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia",[40],"2017-08-29","2018-04-24","2014-03-31",101,[1407],"Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia",[1409,1410],"lipegfilgrastim","pegfilgrastim",{"trials":1412,"activeCount":8},[],{"trials":1414,"activeCount":8},[],{"intervention":1416,"totalTrials":248,"cells":1417},"glatiramer acetate 20 mg",{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1444,"PHASE4":1456,"NA":1458},{"trials":1419,"activeCount":8},[],{"trials":1421,"activeCount":8},[],{"trials":1423,"activeCount":8},[1424,1433],{"nctId":1425,"briefTitle":1426,"status":70,"phases":1427,"primaryCompletion":231,"completion":1428,"start":1429,"enrollment":787,"conditions":1430,"interventions":1431},"NCT00203073","A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.",[39],"2005-04","2003-06",[20],[1416,1432],"glatiramer acetate 20 mg, with mitoxantrone",{"nctId":1434,"briefTitle":1435,"status":70,"phases":1436,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":1439,"conditions":1440,"interventions":1442},"NCT00202982","A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose",[39],"2005-09","2003-08",90,[1441],"Relapse-Remitting Multiple Sclerosis",[1416,1443],"glatiramer acetate 40 mg",{"trials":1445,"activeCount":8},[1446],{"nctId":1447,"briefTitle":1448,"status":70,"phases":1449,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":1453,"interventions":1454},"NCT00337779","Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).",[40],"2008-10","2006-08",1155,[20],[1455,1416],"Glatiramer Acetate (GA) 40 mg",{"trials":1457,"activeCount":8},[],{"trials":1459,"activeCount":8},[],{"intervention":1461,"totalTrials":248,"cells":1462},"TV-1106",{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1480,"PHASE4":1500,"NA":1502},{"trials":1464,"activeCount":8},[],{"trials":1466,"activeCount":8},[],{"trials":1468,"activeCount":8},[1469],{"nctId":1470,"briefTitle":1471,"status":70,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1478},"NCT01811576","Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency",[39],"2013-08-05","2013-03-31",52,[1477],"Growth Hormone Deficiency",[1461,1479],"Recombinant human growth hormone",{"trials":1481,"activeCount":8},[1482,1492],{"nctId":1483,"briefTitle":1484,"status":58,"phases":1485,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":490,"conditions":1489,"interventions":1490},"NCT02410356","Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)",[40],"2016-02-29","2016-04-30","2015-04-30",[1477],[1461,1491],"dGH",{"nctId":1493,"briefTitle":1494,"status":58,"phases":1495,"primaryCompletion":1496,"completion":1496,"start":1488,"enrollment":1497,"conditions":1498,"interventions":1499},"NCT02410343","Study of TV-1106 in Growth Hormone-Deficient Adults",[40],"2015-12-31",14,[1477],[1461],{"trials":1501,"activeCount":8},[],{"trials":1503,"activeCount":8},[],{"intervention":1505,"totalTrials":433,"cells":1506},"ACR16",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1522,"PHASE4":1532,"NA":1534},{"trials":1508,"activeCount":8},[],{"trials":1510,"activeCount":8},[],{"trials":1512,"activeCount":8},[1513],{"nctId":1514,"briefTitle":1515,"status":70,"phases":1516,"primaryCompletion":1517,"completion":1517,"start":731,"enrollment":1518,"conditions":1519,"interventions":1521},"NCT00724048","A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease",[39],"2010-07-26",227,[1520],"Huntington Disease",[1505],{"trials":1523,"activeCount":8},[1524],{"nctId":1525,"briefTitle":1526,"status":70,"phases":1527,"primaryCompletion":1528,"completion":1528,"start":885,"enrollment":1529,"conditions":1530,"interventions":1531},"NCT00665223","A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease",[40],"2010-06-14",437,[823],[1505],{"trials":1533,"activeCount":8},[],{"trials":1535,"activeCount":8},[],{"intervention":850,"totalTrials":433,"cells":1537},{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1542,"PHASE3":1544,"PHASE4":1554,"NA":1556},{"trials":1539,"activeCount":8},[],{"trials":1541,"activeCount":8},[],{"trials":1543,"activeCount":8},[],{"trials":1545,"activeCount":8},[1546,1550],{"nctId":843,"briefTitle":844,"status":845,"phases":1547,"primaryCompletion":83,"completion":83,"start":847,"enrollment":8,"conditions":1548,"interventions":1549},[40],[20],[451,850],{"nctId":881,"briefTitle":882,"status":70,"phases":1551,"primaryCompletion":884,"completion":884,"start":885,"enrollment":886,"conditions":1552,"interventions":1553},[40],[26],[451,850],{"trials":1555,"activeCount":8},[],{"trials":1557,"activeCount":8},[],{"intervention":1559,"totalTrials":433,"cells":1560},"Beclomethasone dipropionate BAI",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1572,"PHASE3":1574,"PHASE4":1586,"NA":1588},{"trials":1562,"activeCount":8},[],{"trials":1564,"activeCount":8},[1565],{"nctId":1566,"briefTitle":1567,"status":70,"phases":1568,"primaryCompletion":105,"completion":970,"start":82,"enrollment":1003,"conditions":1569,"interventions":1570},"NCT02030457","A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults",[38],[28],[1559,1571],"Beclomethasone dipropionate MDI",{"trials":1573,"activeCount":8},[],{"trials":1575,"activeCount":8},[1576],{"nctId":1577,"briefTitle":1578,"status":70,"phases":1579,"primaryCompletion":1580,"completion":1581,"start":82,"enrollment":1582,"conditions":1583,"interventions":1584},"NCT02040766","A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma",[40],"2016-02","2016-03",628,[14],[1559,1585,1571],"albuterol\u002Fsalbutamol 90 mcg",{"trials":1587,"activeCount":8},[],{"trials":1589,"activeCount":8},[],{"intervention":1571,"totalTrials":433,"cells":1591},{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1600,"PHASE3":1602,"PHASE4":1608,"NA":1610},{"trials":1593,"activeCount":8},[],{"trials":1595,"activeCount":8},[1596],{"nctId":1566,"briefTitle":1567,"status":70,"phases":1597,"primaryCompletion":105,"completion":970,"start":82,"enrollment":1003,"conditions":1598,"interventions":1599},[38],[28],[1559,1571],{"trials":1601,"activeCount":8},[],{"trials":1603,"activeCount":8},[1604],{"nctId":1577,"briefTitle":1578,"status":70,"phases":1605,"primaryCompletion":1580,"completion":1581,"start":82,"enrollment":1582,"conditions":1606,"interventions":1607},[40],[14],[1559,1585,1571],{"trials":1609,"activeCount":8},[],{"trials":1611,"activeCount":8},[],{"intervention":1613,"totalTrials":433,"cells":1614},"tbo-filgrastim",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1631,"PHASE4":1643,"NA":1645},{"trials":1616,"activeCount":8},[],{"trials":1618,"activeCount":8},[],{"trials":1620,"activeCount":8},[1621],{"nctId":1622,"briefTitle":1623,"status":70,"phases":1624,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1627,"conditions":1628,"interventions":1630},"NCT02190721","A Study to Evaluate 5 μg\u002Fkg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement",[39],"2017-04-04","2015-05-12",50,[1629],"Neutropenia",[1613],{"trials":1632,"activeCount":8},[1633],{"nctId":1634,"briefTitle":1635,"status":58,"phases":1636,"primaryCompletion":1637,"completion":1637,"start":1638,"enrollment":538,"conditions":1639,"interventions":1641},"NCT03029000","Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants",[40],"2017-10-30","2017-08-02",[1640],"Healthy Participants",[1642],"Tbo-filgrastim",{"trials":1644,"activeCount":8},[],{"trials":1646,"activeCount":8},[],{"intervention":1006,"totalTrials":433,"cells":1648},{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1659,"PHASE4":1665,"NA":1667},{"trials":1650,"activeCount":8},[],{"trials":1652,"activeCount":8},[],{"trials":1654,"activeCount":8},[1655],{"nctId":999,"briefTitle":1000,"status":70,"phases":1656,"primaryCompletion":311,"completion":311,"start":1002,"enrollment":1003,"conditions":1657,"interventions":1658},[39],[14],[404,974,1006,294],{"trials":1660,"activeCount":8},[1661],{"nctId":1018,"briefTitle":1019,"status":70,"phases":1662,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":1663,"interventions":1664},[40],[1025],[404,974,1027,1028,1029],{"trials":1666,"activeCount":8},[],{"trials":1668,"activeCount":8},[],{"intervention":1385,"totalTrials":433,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1686,"PHASE4":1692,"NA":1694},{"trials":1672,"activeCount":8},[],{"trials":1674,"activeCount":8},[],{"trials":1676,"activeCount":8},[1677],{"nctId":1678,"briefTitle":1679,"status":845,"phases":1680,"primaryCompletion":1681,"completion":1682,"start":784,"enrollment":8,"conditions":1683,"interventions":1684},"NCT01940601","Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors",[39],"2015-11","2015-12",[33],[1385,1685],"Filgrastim",{"trials":1687,"activeCount":8},[1688],{"nctId":1376,"briefTitle":1377,"status":70,"phases":1689,"primaryCompletion":1379,"completion":1379,"start":1380,"enrollment":1381,"conditions":1690,"interventions":1691},[39,40],[1383],[1385,1365,1386],{"trials":1693,"activeCount":8},[],{"trials":1695,"activeCount":8},[],{"intervention":1697,"totalTrials":433,"cells":1698},"TV-46000",{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1703,"PHASE3":1705,"PHASE4":1727,"NA":1729},{"trials":1700,"activeCount":8},[],{"trials":1702,"activeCount":8},[],{"trials":1704,"activeCount":8},[],{"trials":1706,"activeCount":8},[1707,1717],{"nctId":1708,"briefTitle":1709,"status":70,"phases":1710,"primaryCompletion":1711,"completion":1711,"start":1712,"enrollment":1713,"conditions":1714,"interventions":1716},"NCT03893825","A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia",[40],"2021-12-02","2019-04-17",336,[1715],"Schizophrenia",[1697],{"nctId":1718,"briefTitle":1719,"status":70,"phases":1720,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1726},"NCT03503318","Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia",[40],"2020-09-30","2020-12-03","2018-04-27",544,[1715],[1697],{"trials":1728,"activeCount":8},[],{"trials":1730,"activeCount":8},[],{"intervention":1732,"totalTrials":433,"cells":1733},"Albuterol Sulfate",{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1740,"PHASE4":1762,"NA":1764},{"trials":1735,"activeCount":8},[],{"trials":1737,"activeCount":8},[],{"trials":1739,"activeCount":8},[],{"trials":1741,"activeCount":8},[1742,1751],{"nctId":1743,"briefTitle":1744,"status":70,"phases":1745,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1750},"NCT02969408","A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma",[40],"2018-02-02","2017-02-13",397,[14],[1732],{"nctId":1752,"briefTitle":1753,"status":70,"phases":1754,"primaryCompletion":1755,"completion":1755,"start":1756,"enrollment":1757,"conditions":1758,"interventions":1760},"NCT03256695","Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)",[40],"2018-04-17","2017-09-28",405,[1759],"Chronic Obstructive Pulmonary Disease",[1761],"Albuterol sulfate",{"trials":1763,"activeCount":8},[],{"trials":1765,"activeCount":8},[],{"intervention":362,"totalTrials":433,"cells":1767},{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1772,"PHASE3":1783,"PHASE4":1789,"NA":1791},{"trials":1769,"activeCount":8},[],{"trials":1771,"activeCount":8},[],{"trials":1773,"activeCount":8},[1774],{"nctId":1775,"briefTitle":1776,"status":70,"phases":1777,"primaryCompletion":1202,"completion":1202,"start":1778,"enrollment":464,"conditions":1779,"interventions":1781},"NCT01088984","Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia",[38,39],"2010-08",[1780],"Leukemia",[1782],"Bendamustine",{"trials":1784,"activeCount":8},[1785],{"nctId":352,"briefTitle":353,"status":70,"phases":1786,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":1787,"interventions":1788},[40],[359,360],[362,363,364,365,366,367],{"trials":1790,"activeCount":8},[],{"trials":1792,"activeCount":8},[],{"intervention":363,"totalTrials":433,"cells":1794},{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1808,"PHASE3":1810,"PHASE4":1816,"NA":1818},{"trials":1796,"activeCount":8},[],{"trials":1798,"activeCount":8},[1799],{"nctId":1800,"briefTitle":1801,"status":70,"phases":1802,"primaryCompletion":399,"completion":132,"start":372,"enrollment":1265,"conditions":1803,"interventions":1805},"NCT01205737","A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects",[38],[1804],"DLBCL",[1806,1807],"TL011","Rituximab",{"trials":1809,"activeCount":8},[],{"trials":1811,"activeCount":8},[1812],{"nctId":352,"briefTitle":353,"status":70,"phases":1813,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":1814,"interventions":1815},[40],[359,360],[362,363,364,365,366,367],{"trials":1817,"activeCount":8},[],{"trials":1819,"activeCount":8},[],{"intervention":192,"totalTrials":538,"cells":1821},{"EARLY_PHASE1":1822,"PHASE1":1824,"PHASE2":1826,"PHASE3":1828,"PHASE4":1834,"NA":1836},{"trials":1823,"activeCount":8},[],{"trials":1825,"activeCount":8},[],{"trials":1827,"activeCount":8},[],{"trials":1829,"activeCount":8},[1830],{"nctId":183,"briefTitle":184,"status":70,"phases":1831,"primaryCompletion":186,"completion":187,"start":188,"enrollment":189,"conditions":1832,"interventions":1833},[40],[20],[151,192],{"trials":1835,"activeCount":8},[],{"trials":1837,"activeCount":8},[],{"intervention":1839,"totalTrials":538,"cells":1840},"BDP Nasal Aerosol",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1847,"PHASE4":1857,"NA":1859},{"trials":1842,"activeCount":8},[],{"trials":1844,"activeCount":8},[],{"trials":1846,"activeCount":8},[],{"trials":1848,"activeCount":8},[1849],{"nctId":1850,"briefTitle":1851,"status":70,"phases":1852,"primaryCompletion":410,"completion":410,"start":1002,"enrollment":1853,"conditions":1854,"interventions":1856},"NCT01783548","Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)",[40],547,[1855],"Allergic Rhinitis",[1839],{"trials":1858,"activeCount":8},[],{"trials":1860,"activeCount":8},[],{"intervention":1862,"totalTrials":538,"cells":1863},"DR-1021",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1870,"PHASE4":1883,"NA":1885},{"trials":1865,"activeCount":8},[],{"trials":1867,"activeCount":8},[],{"trials":1869,"activeCount":8},[],{"trials":1871,"activeCount":8},[1872],{"nctId":1873,"briefTitle":1874,"status":70,"phases":1875,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1299,"conditions":1878,"interventions":1880},"NCT00544882","A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021",[40],"2008-03-31","2007-10-31",[1879],"Healthy",[1862,1881,1882],"Mircette®","Kariva®",{"trials":1884,"activeCount":8},[],{"trials":1886,"activeCount":8},[],{"intervention":1881,"totalTrials":538,"cells":1888},{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1901,"NA":1903},{"trials":1890,"activeCount":8},[],{"trials":1892,"activeCount":8},[],{"trials":1894,"activeCount":8},[],{"trials":1896,"activeCount":8},[1897],{"nctId":1873,"briefTitle":1874,"status":70,"phases":1898,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1299,"conditions":1899,"interventions":1900},[40],[1879],[1862,1881,1882],{"trials":1902,"activeCount":8},[],{"trials":1904,"activeCount":8},[],{"intervention":1882,"totalTrials":538,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1913,"PHASE4":1919,"NA":1921},{"trials":1908,"activeCount":8},[],{"trials":1910,"activeCount":8},[],{"trials":1912,"activeCount":8},[],{"trials":1914,"activeCount":8},[1915],{"nctId":1873,"briefTitle":1874,"status":70,"phases":1916,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1299,"conditions":1917,"interventions":1918},[40],[1879],[1862,1881,1882],{"trials":1920,"activeCount":8},[],{"trials":1922,"activeCount":8},[],{"intervention":1924,"totalTrials":538,"cells":1925},"Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol",{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1932,"PHASE4":1941,"NA":1943},{"trials":1927,"activeCount":8},[],{"trials":1929,"activeCount":8},[],{"trials":1931,"activeCount":8},[],{"trials":1933,"activeCount":8},[1934],{"nctId":1935,"briefTitle":1936,"status":70,"phases":1937,"primaryCompletion":462,"completion":462,"start":810,"enrollment":1938,"conditions":1939,"interventions":1940},"NCT01134705","Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)",[40],474,[943],[1924],{"trials":1942,"activeCount":8},[],{"trials":1944,"activeCount":8},[],{"intervention":1946,"totalTrials":538,"cells":1947},"SD-809",{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1952,"PHASE3":1954,"PHASE4":1964,"NA":1966},{"trials":1949,"activeCount":8},[],{"trials":1951,"activeCount":8},[],{"trials":1953,"activeCount":8},[],{"trials":1955,"activeCount":8},[1956],{"nctId":1957,"briefTitle":1958,"status":70,"phases":1959,"primaryCompletion":1960,"completion":1960,"start":1473,"enrollment":1439,"conditions":1961,"interventions":1963},"NCT01795859","First Time Use of SD-809 in Huntington Disease",[40],"2014-12-05",[1962],"Chorea",[1946],{"trials":1965,"activeCount":8},[],{"trials":1967,"activeCount":8},[],{"intervention":1074,"totalTrials":538,"cells":1969},{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1982,"NA":1984},{"trials":1971,"activeCount":8},[],{"trials":1973,"activeCount":8},[],{"trials":1975,"activeCount":8},[],{"trials":1977,"activeCount":8},[1978],{"nctId":1066,"briefTitle":1067,"status":70,"phases":1979,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":1071,"conditions":1980,"interventions":1981},[40],[1025],[1074,405],{"trials":1983,"activeCount":8},[],{"trials":1985,"activeCount":8},[],{"intervention":1987,"totalTrials":538,"cells":1988},"BDP",{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":1993,"PHASE3":1995,"PHASE4":2005,"NA":2007},{"trials":1990,"activeCount":8},[],{"trials":1992,"activeCount":8},[],{"trials":1994,"activeCount":8},[],{"trials":1996,"activeCount":8},[1997],{"nctId":1998,"briefTitle":1999,"status":70,"phases":2000,"primaryCompletion":2001,"completion":2001,"start":165,"enrollment":2002,"conditions":2003,"interventions":2004},"NCT01697956","Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)",[40],"2013-02",99,[1855],[1987],{"trials":2006,"activeCount":8},[],{"trials":2008,"activeCount":8},[],{"intervention":1386,"totalTrials":538,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2017,"PHASE4":2023,"NA":2025},{"trials":2012,"activeCount":8},[],{"trials":2014,"activeCount":8},[],{"trials":2016,"activeCount":8},[],{"trials":2018,"activeCount":8},[2019],{"nctId":1376,"briefTitle":1377,"status":70,"phases":2020,"primaryCompletion":1379,"completion":1379,"start":1380,"enrollment":1381,"conditions":2021,"interventions":2022},[39,40],[1383],[1385,1365,1386],{"trials":2024,"activeCount":8},[],{"trials":2026,"activeCount":8},[],{"intervention":2028,"totalTrials":538,"cells":2029},"GA 20 mg\u002FmL",{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2036,"PHASE4":2046,"NA":2048},{"trials":2031,"activeCount":8},[],{"trials":2033,"activeCount":8},[],{"trials":2035,"activeCount":8},[],{"trials":2037,"activeCount":8},[2038],{"nctId":2039,"briefTitle":2040,"status":70,"phases":2041,"primaryCompletion":105,"completion":1264,"start":311,"enrollment":2042,"conditions":2043,"interventions":2044},"NCT01874145","Safety and Tolerability of Glatiramer Acetate",[40],209,[170],[2028,2045],"GA 40 mg\u002FmL",{"trials":2047,"activeCount":8},[],{"trials":2049,"activeCount":8},[],{"intervention":2045,"totalTrials":538,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2058,"PHASE4":2064,"NA":2066},{"trials":2053,"activeCount":8},[],{"trials":2055,"activeCount":8},[],{"trials":2057,"activeCount":8},[],{"trials":2059,"activeCount":8},[2060],{"nctId":2039,"briefTitle":2040,"status":70,"phases":2061,"primaryCompletion":105,"completion":1264,"start":311,"enrollment":2042,"conditions":2062,"interventions":2063},[40],[170],[2028,2045],{"trials":2065,"activeCount":8},[],{"trials":2067,"activeCount":8},[],{"intervention":1268,"totalTrials":538,"cells":2069},{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2082,"NA":2084},{"trials":2071,"activeCount":8},[],{"trials":2073,"activeCount":8},[],{"trials":2075,"activeCount":8},[],{"trials":2077,"activeCount":8},[2078],{"nctId":1260,"briefTitle":1261,"status":70,"phases":2079,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":2080,"interventions":2081},[40],[14],[1241,1268],{"trials":2083,"activeCount":8},[],{"trials":2085,"activeCount":8},[],{"intervention":1027,"totalTrials":538,"cells":2087},{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2094,"PHASE4":2100,"NA":2102},{"trials":2089,"activeCount":8},[],{"trials":2091,"activeCount":8},[],{"trials":2093,"activeCount":8},[],{"trials":2095,"activeCount":8},[2096],{"nctId":1018,"briefTitle":1019,"status":70,"phases":2097,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":2098,"interventions":2099},[40],[1025],[404,974,1027,1028,1029],{"trials":2101,"activeCount":8},[],{"trials":2103,"activeCount":8},[],{"intervention":1029,"totalTrials":538,"cells":2105},{"EARLY_PHASE1":2106,"PHASE1":2108,"PHASE2":2110,"PHASE3":2112,"PHASE4":2118,"NA":2120},{"trials":2107,"activeCount":8},[],{"trials":2109,"activeCount":8},[],{"trials":2111,"activeCount":8},[],{"trials":2113,"activeCount":8},[2114],{"nctId":1018,"briefTitle":1019,"status":70,"phases":2115,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":2116,"interventions":2117},[40],[1025],[404,974,1027,1028,1029],{"trials":2119,"activeCount":8},[],{"trials":2121,"activeCount":8},[],{"intervention":1037,"totalTrials":538,"cells":2123},{"EARLY_PHASE1":2124,"PHASE1":2126,"PHASE2":2128,"PHASE3":2130,"PHASE4":2136,"NA":2138},{"trials":2125,"activeCount":8},[],{"trials":2127,"activeCount":8},[],{"trials":2129,"activeCount":8},[],{"trials":2131,"activeCount":8},[2132],{"nctId":1031,"briefTitle":1032,"status":70,"phases":2133,"primaryCompletion":969,"completion":969,"start":970,"enrollment":1034,"conditions":2134,"interventions":2135},[40],[14],[974,404,1037],{"trials":2137,"activeCount":8},[],{"trials":2139,"activeCount":8},[],{"intervention":1084,"totalTrials":538,"cells":2141},{"EARLY_PHASE1":2142,"PHASE1":2144,"PHASE2":2146,"PHASE3":2148,"PHASE4":2154,"NA":2156},{"trials":2143,"activeCount":8},[],{"trials":2145,"activeCount":8},[],{"trials":2147,"activeCount":8},[],{"trials":2149,"activeCount":8},[2150],{"nctId":1076,"briefTitle":1077,"status":70,"phases":2151,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":2152,"interventions":2153},[40],[1025],[1084,1085,405,1086],{"trials":2155,"activeCount":8},[],{"trials":2157,"activeCount":8},[],{"intervention":1085,"totalTrials":538,"cells":2159},{"EARLY_PHASE1":2160,"PHASE1":2162,"PHASE2":2164,"PHASE3":2166,"PHASE4":2172,"NA":2174},{"trials":2161,"activeCount":8},[],{"trials":2163,"activeCount":8},[],{"trials":2165,"activeCount":8},[],{"trials":2167,"activeCount":8},[2168],{"nctId":1076,"briefTitle":1077,"status":70,"phases":2169,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":2170,"interventions":2171},[40],[1025],[1084,1085,405,1086],{"trials":2173,"activeCount":8},[],{"trials":2175,"activeCount":8},[],{"intervention":1086,"totalTrials":538,"cells":2177},{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2184,"PHASE4":2190,"NA":2192},{"trials":2179,"activeCount":8},[],{"trials":2181,"activeCount":8},[],{"trials":2183,"activeCount":8},[],{"trials":2185,"activeCount":8},[2186],{"nctId":1076,"briefTitle":1077,"status":70,"phases":2187,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":2188,"interventions":2189},[40],[1025],[1084,1085,405,1086],{"trials":2191,"activeCount":8},[],{"trials":2193,"activeCount":8},[],{"intervention":2195,"totalTrials":538,"cells":2196},"DR-102",{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2201,"PHASE3":2203,"PHASE4":2214,"NA":2216},{"trials":2198,"activeCount":8},[],{"trials":2200,"activeCount":8},[],{"trials":2202,"activeCount":8},[],{"trials":2204,"activeCount":8},[2205],{"nctId":2206,"briefTitle":2207,"status":70,"phases":2208,"primaryCompletion":1002,"completion":1002,"start":1778,"enrollment":2209,"conditions":2210,"interventions":2213},"NCT01178125","A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy",[40],2858,[2211,2212],"Contraception","Female Contraception",[2195],{"trials":2215,"activeCount":8},[],{"trials":2217,"activeCount":8},[],{"intervention":2219,"totalTrials":538,"cells":2220},"rasagiline mesylate 1.0 mg",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2239,"NA":2241},{"trials":2222,"activeCount":8},[],{"trials":2224,"activeCount":8},[],{"trials":2226,"activeCount":8},[],{"trials":2228,"activeCount":8},[2229],{"nctId":2230,"briefTitle":2231,"status":70,"phases":2232,"primaryCompletion":2233,"start":2234,"enrollment":2235,"conditions":2236,"interventions":2237},"NCT00203177","Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa\u002FCarbidopa Therapy.",[40],"2006-12","2001-10",254,[17],[2238,2219],"rasagiline mesylate",{"trials":2240,"activeCount":8},[],{"trials":2242,"activeCount":8},[],{"intervention":1455,"totalTrials":538,"cells":2244},{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2251,"PHASE4":2257,"NA":2259},{"trials":2246,"activeCount":8},[],{"trials":2248,"activeCount":8},[],{"trials":2250,"activeCount":8},[],{"trials":2252,"activeCount":8},[2253],{"nctId":1447,"briefTitle":1448,"status":70,"phases":2254,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":2255,"interventions":2256},[40],[20],[1455,1416],{"trials":2258,"activeCount":8},[],{"trials":2260,"activeCount":8},[],{"intervention":2262,"totalTrials":538,"cells":2263},"Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX",{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2270,"PHASE4":2282,"NA":2284},{"trials":2265,"activeCount":8},[],{"trials":2267,"activeCount":8},[],{"trials":2269,"activeCount":8},[],{"trials":2271,"activeCount":8},[2272],{"nctId":2273,"briefTitle":2274,"status":70,"phases":2275,"primaryCompletion":2276,"completion":2276,"start":2277,"enrollment":2278,"conditions":2279,"interventions":2280},"NCT02062463","Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma",[40],"2015-03-13","2014-05-28",485,[14],[2262,2281],"SYMBICORT TURBOHALER budesonide and formoterol fumarate",{"trials":2283,"activeCount":8},[],{"trials":2285,"activeCount":8},[],{"intervention":2281,"totalTrials":538,"cells":2287},{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2300,"NA":2302},{"trials":2289,"activeCount":8},[],{"trials":2291,"activeCount":8},[],{"trials":2293,"activeCount":8},[],{"trials":2295,"activeCount":8},[2296],{"nctId":2273,"briefTitle":2274,"status":70,"phases":2297,"primaryCompletion":2276,"completion":2276,"start":2277,"enrollment":2278,"conditions":2298,"interventions":2299},[40],[14],[2262,2281],{"trials":2301,"activeCount":8},[],{"trials":2303,"activeCount":8},[],{"intervention":2305,"totalTrials":538,"cells":2306},"albuterol aerosol by HFA MDI",{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2326,"NA":2328},{"trials":2308,"activeCount":8},[],{"trials":2310,"activeCount":8},[],{"trials":2312,"activeCount":8},[],{"trials":2314,"activeCount":8},[2315],{"nctId":2316,"briefTitle":2317,"status":70,"phases":2318,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":2322,"interventions":2324},"NCT00085774","Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma",[40],"2004-09-30","2004-06-30",24,[2323],"Exercise-induced Bronchospasm",[2305,2325],"albuterol aerosol by HFA BOI",{"trials":2327,"activeCount":8},[],{"trials":2329,"activeCount":8},[],{"intervention":2325,"totalTrials":538,"cells":2331},{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2338,"PHASE4":2344,"NA":2346},{"trials":2333,"activeCount":8},[],{"trials":2335,"activeCount":8},[],{"trials":2337,"activeCount":8},[],{"trials":2339,"activeCount":8},[2340],{"nctId":2316,"briefTitle":2317,"status":70,"phases":2341,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":2342,"interventions":2343},[40],[2323],[2305,2325],{"trials":2345,"activeCount":8},[],{"trials":2347,"activeCount":8},[],{"intervention":280,"totalTrials":538,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2356,"PHASE4":2362,"NA":2364},{"trials":2351,"activeCount":8},[],{"trials":2353,"activeCount":8},[],{"trials":2355,"activeCount":8},[],{"trials":2357,"activeCount":8},[2358],{"nctId":271,"briefTitle":272,"status":70,"phases":2359,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":2360,"interventions":2361},[40],[14],[280,281],{"trials":2363,"activeCount":8},[],{"trials":2365,"activeCount":8},[],{"intervention":1491,"totalTrials":538,"cells":2367},{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2372,"PHASE3":2374,"PHASE4":2380,"NA":2382},{"trials":2369,"activeCount":8},[],{"trials":2371,"activeCount":8},[],{"trials":2373,"activeCount":8},[],{"trials":2375,"activeCount":8},[2376],{"nctId":1483,"briefTitle":1484,"status":58,"phases":2377,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":490,"conditions":2378,"interventions":2379},[40],[1477],[1461,1491],{"trials":2381,"activeCount":8},[],{"trials":2383,"activeCount":8},[],{"intervention":2385,"totalTrials":538,"cells":2386},"BDP HFA",{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2404,"NA":2406},{"trials":2388,"activeCount":8},[],{"trials":2390,"activeCount":8},[],{"trials":2392,"activeCount":8},[],{"trials":2394,"activeCount":8},[2395],{"nctId":2396,"briefTitle":2397,"status":70,"phases":2398,"primaryCompletion":2399,"completion":1202,"start":106,"enrollment":2400,"conditions":2401,"interventions":2403},"NCT01307319","Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies",[40],"2011-07",715,[953,2402],"SAR",[2385],{"trials":2405,"activeCount":8},[],{"trials":2407,"activeCount":8},[],{"intervention":364,"totalTrials":538,"cells":2409},{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2414,"PHASE3":2416,"PHASE4":2422,"NA":2424},{"trials":2411,"activeCount":8},[],{"trials":2413,"activeCount":8},[],{"trials":2415,"activeCount":8},[],{"trials":2417,"activeCount":8},[2418],{"nctId":352,"briefTitle":353,"status":70,"phases":2419,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":2420,"interventions":2421},[40],[359,360],[362,363,364,365,366,367],{"trials":2423,"activeCount":8},[],{"trials":2425,"activeCount":8},[],{"intervention":366,"totalTrials":538,"cells":2427},{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2434,"PHASE4":2440,"NA":2442},{"trials":2429,"activeCount":8},[],{"trials":2431,"activeCount":8},[],{"trials":2433,"activeCount":8},[],{"trials":2435,"activeCount":8},[2436],{"nctId":352,"briefTitle":353,"status":70,"phases":2437,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":2438,"interventions":2439},[40],[359,360],[362,363,364,365,366,367],{"trials":2441,"activeCount":8},[],{"trials":2443,"activeCount":8},[],{"intervention":367,"totalTrials":538,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2458,"NA":2460},{"trials":2447,"activeCount":8},[],{"trials":2449,"activeCount":8},[],{"trials":2451,"activeCount":8},[],{"trials":2453,"activeCount":8},[2454],{"nctId":352,"briefTitle":353,"status":70,"phases":2455,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":2456,"interventions":2457},[40],[359,360],[362,363,364,365,366,367],{"trials":2459,"activeCount":8},[],{"trials":2461,"activeCount":8},[],{"intervention":2463,"totalTrials":538,"cells":2464},"TV-46763",{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2483,"NA":2485},{"trials":2466,"activeCount":8},[],{"trials":2468,"activeCount":8},[],{"trials":2470,"activeCount":8},[],{"trials":2472,"activeCount":8},[2473],{"nctId":2474,"briefTitle":2475,"status":70,"phases":2476,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":2479,"conditions":2480,"interventions":2482},"NCT02487108","Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate\u002FAcetaminophen Immediate-Release Tablets in Participants With Moderate to Severe Pain Following Bunionectomy",[40],"2016-03-30","2015-08-11",569,[2481],"Pain",[2463],{"trials":2484,"activeCount":8},[],{"trials":2486,"activeCount":8},[],{"intervention":1396,"totalTrials":538,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2501,"NA":2503},{"trials":2490,"activeCount":8},[],{"trials":2492,"activeCount":8},[],{"trials":2494,"activeCount":8},[],{"trials":2496,"activeCount":8},[2497],{"nctId":1388,"briefTitle":1389,"status":70,"phases":2498,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":2499,"interventions":2500},[40],[1383],[1396,1365,1397],{"trials":2502,"activeCount":8},[],{"trials":2504,"activeCount":8},[],{"intervention":1397,"totalTrials":538,"cells":2506},{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2513,"PHASE4":2519,"NA":2521},{"trials":2508,"activeCount":8},[],{"trials":2510,"activeCount":8},[],{"trials":2512,"activeCount":8},[],{"trials":2514,"activeCount":8},[2515],{"nctId":1388,"briefTitle":1389,"status":70,"phases":2516,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":2517,"interventions":2518},[40],[1383],[1396,1365,1397],{"trials":2520,"activeCount":8},[],{"trials":2522,"activeCount":8},[],{"intervention":99,"totalTrials":538,"cells":2524},{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2531,"PHASE4":2537,"NA":2539},{"trials":2526,"activeCount":8},[],{"trials":2528,"activeCount":8},[],{"trials":2530,"activeCount":8},[],{"trials":2532,"activeCount":8},[2533],{"nctId":89,"briefTitle":90,"status":70,"phases":2534,"primaryCompletion":92,"completion":72,"start":93,"enrollment":94,"conditions":2535,"interventions":2536},[40],[14,96,97],[45,99,100],{"trials":2538,"activeCount":8},[],{"trials":2540,"activeCount":8},[],{"intervention":100,"totalTrials":538,"cells":2542},{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2547,"PHASE3":2549,"PHASE4":2555,"NA":2557},{"trials":2544,"activeCount":8},[],{"trials":2546,"activeCount":8},[],{"trials":2548,"activeCount":8},[],{"trials":2550,"activeCount":8},[2551],{"nctId":89,"briefTitle":90,"status":70,"phases":2552,"primaryCompletion":92,"completion":72,"start":93,"enrollment":94,"conditions":2553,"interventions":2554},[40],[14,96,97],[45,99,100],{"trials":2556,"activeCount":8},[],{"trials":2558,"activeCount":8},[],{"intervention":1409,"totalTrials":538,"cells":2560},{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2567,"PHASE4":2573,"NA":2575},{"trials":2562,"activeCount":8},[],{"trials":2564,"activeCount":8},[],{"trials":2566,"activeCount":8},[],{"trials":2568,"activeCount":8},[2569],{"nctId":1399,"briefTitle":1400,"status":70,"phases":2570,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":2571,"interventions":2572},[40],[1407],[1409,1410],{"trials":2574,"activeCount":8},[],{"trials":2576,"activeCount":8},[],{"intervention":1585,"totalTrials":538,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2585,"PHASE4":2591,"NA":2593},{"trials":2580,"activeCount":8},[],{"trials":2582,"activeCount":8},[],{"trials":2584,"activeCount":8},[],{"trials":2586,"activeCount":8},[2587],{"nctId":1577,"briefTitle":1578,"status":70,"phases":2588,"primaryCompletion":1580,"completion":1581,"start":82,"enrollment":1582,"conditions":2589,"interventions":2590},[40],[14],[1559,1585,1571],{"trials":2592,"activeCount":8},[],{"trials":2594,"activeCount":8},[],{"intervention":2596,"totalTrials":538,"cells":2597},"Proventil® HFA",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2615,"NA":2617},{"trials":2599,"activeCount":8},[],{"trials":2601,"activeCount":8},[],{"trials":2603,"activeCount":8},[],{"trials":2605,"activeCount":8},[2606],{"nctId":2607,"briefTitle":2608,"status":70,"phases":2609,"primaryCompletion":2610,"completion":2610,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2614},"NCT00577655","Albuterol HFA MDI in Pediatric Participants With Asthma",[40],"2008-07","2007-08",103,[14],[294,2596],{"trials":2616,"activeCount":8},[],{"trials":2618,"activeCount":8},[],{"intervention":2620,"totalTrials":538,"cells":2621},"Budesonide\u002FFormoterol SPIROMAX®",{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2628,"PHASE4":2642,"NA":2644},{"trials":2623,"activeCount":8},[],{"trials":2625,"activeCount":8},[],{"trials":2627,"activeCount":8},[],{"trials":2629,"activeCount":8},[2630],{"nctId":2631,"briefTitle":2632,"status":70,"phases":2633,"primaryCompletion":2634,"completion":2634,"start":2635,"enrollment":2636,"conditions":2637,"interventions":2638},"NCT01803555","Efficacy and Safety Evaluation of Budesonide\u002FFormoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®",[40],"2014-03-20","2013-07-04",605,[14],[2620,2639,2640,2641],"SYMBICORT® TURBOHALER®","SYMBICORT placebo","SPIROMAX Placebo",{"trials":2643,"activeCount":8},[],{"trials":2645,"activeCount":8},[],{"intervention":2639,"totalTrials":538,"cells":2647},{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2660,"NA":2662},{"trials":2649,"activeCount":8},[],{"trials":2651,"activeCount":8},[],{"trials":2653,"activeCount":8},[],{"trials":2655,"activeCount":8},[2656],{"nctId":2631,"briefTitle":2632,"status":70,"phases":2657,"primaryCompletion":2634,"completion":2634,"start":2635,"enrollment":2636,"conditions":2658,"interventions":2659},[40],[14],[2620,2639,2640,2641],{"trials":2661,"activeCount":8},[],{"trials":2663,"activeCount":8},[],{"intervention":2640,"totalTrials":538,"cells":2665},{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2672,"PHASE4":2678,"NA":2680},{"trials":2667,"activeCount":8},[],{"trials":2669,"activeCount":8},[],{"trials":2671,"activeCount":8},[],{"trials":2673,"activeCount":8},[2674],{"nctId":2631,"briefTitle":2632,"status":70,"phases":2675,"primaryCompletion":2634,"completion":2634,"start":2635,"enrollment":2636,"conditions":2676,"interventions":2677},[40],[14],[2620,2639,2640,2641],{"trials":2679,"activeCount":8},[],{"trials":2681,"activeCount":8},[],{"intervention":2641,"totalTrials":538,"cells":2683},{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2688,"PHASE3":2690,"PHASE4":2696,"NA":2698},{"trials":2685,"activeCount":8},[],{"trials":2687,"activeCount":8},[],{"trials":2689,"activeCount":8},[],{"trials":2691,"activeCount":8},[2692],{"nctId":2631,"briefTitle":2632,"status":70,"phases":2693,"primaryCompletion":2634,"completion":2634,"start":2635,"enrollment":2636,"conditions":2694,"interventions":2695},[40],[14],[2620,2639,2640,2641],{"trials":2697,"activeCount":8},[],{"trials":2699,"activeCount":8},[],{"intervention":2701,"totalTrials":538,"cells":2702},"1.0 mg rasagiline mesylate",{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2707,"PHASE3":2709,"PHASE4":2720,"NA":2722},{"trials":2704,"activeCount":8},[],{"trials":2706,"activeCount":8},[],{"trials":2708,"activeCount":8},[],{"trials":2710,"activeCount":8},[2711],{"nctId":2712,"briefTitle":2713,"status":70,"phases":2714,"primaryCompletion":2715,"completion":2715,"start":2716,"enrollment":2717,"conditions":2718,"interventions":2719},"NCT00203034","Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations",[40],"2003-01","2000-05",472,[17],[2238,2701],{"trials":2721,"activeCount":8},[],{"trials":2723,"activeCount":8},[],{"intervention":2725,"totalTrials":538,"cells":2726},"Bendamustine hydrochloride",{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2733,"PHASE4":2746,"NA":2748},{"trials":2728,"activeCount":8},[],{"trials":2730,"activeCount":8},[],{"trials":2732,"activeCount":8},[],{"trials":2734,"activeCount":8},[2735],{"nctId":2736,"briefTitle":2737,"status":70,"phases":2738,"primaryCompletion":2739,"completion":2740,"start":2741,"enrollment":2742,"conditions":2743,"interventions":2745},"NCT01596621","A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment",[40],"2015-06-18","2017-04-24","2012-08-06",102,[2744],"Non-Hodgkin Lymphoma",[2725],{"trials":2747,"activeCount":8},[],{"trials":2749,"activeCount":8},[],{"intervention":2751,"totalTrials":11,"cells":2752},"Talampanel",{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2767,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2754,"activeCount":8},[],{"trials":2756,"activeCount":8},[2757],{"nctId":2758,"briefTitle":2759,"status":70,"phases":2760,"primaryCompletion":2761,"completion":1347,"start":2762,"enrollment":2763,"conditions":2764,"interventions":2765},"NCT00964730","A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm",[38],"2010-01","2009-10",135,[1879],[2751,2766],"Moxifloxacin",{"trials":2768,"activeCount":8},[2769,2777,2787,2799,2809,2821],{"nctId":2770,"briefTitle":2771,"status":58,"phases":2772,"primaryCompletion":198,"completion":198,"start":186,"enrollment":2773,"conditions":2774,"interventions":2776},"NCT00982150","Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)",[39],446,[2775],"Amyotrophic Lateral Sclerosis",[2751],{"nctId":2778,"briefTitle":2779,"status":70,"phases":2780,"primaryCompletion":2781,"completion":2781,"start":2782,"enrollment":2783,"conditions":2784,"interventions":2786},"NCT00034814","Multicenter Trial for Adults With Partial Seizures",[39],"2006-01","2002-01",190,[2785],"Epilepsy",[2751,2751,2751,2751],{"nctId":2788,"briefTitle":2789,"status":58,"phases":2790,"primaryCompletion":2781,"completion":2791,"start":2792,"enrollment":992,"conditions":2793,"interventions":2798},"NCT00062504","Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas",[39],"2006-04","2003-07",[2794,2795,2796,2797],"Glioblastoma Multiforme","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Anaplastic Mixed Oligoastrocytoma",[2751],{"nctId":2800,"briefTitle":2801,"status":70,"phases":2802,"primaryCompletion":2803,"completion":133,"start":2804,"enrollment":1003,"conditions":2805,"interventions":2806},"NCT00267592","Safety and Efficacy of Talampanel in Glioblastoma Multiforme",[39],"2008-09","2005-12",[2794],[2751,2807,2808],"temozolomide(TMZ) 75mg","adjuvant TMZ 200mg",{"nctId":2810,"briefTitle":2811,"status":70,"phases":2812,"primaryCompletion":2813,"completion":2813,"start":2233,"enrollment":2814,"conditions":2815,"interventions":2819},"NCT00036296","Effects of Talampanel on Patients With Advanced Parkinson's Disease",[38,39],"2007-02",22,[2816,2817,2818],"Dyskinesias","Parkinson Disease","Movement Disorders",[2820],"talampanel",{"nctId":2822,"briefTitle":2823,"status":70,"phases":2824,"primaryCompletion":2825,"completion":810,"start":2803,"enrollment":2826,"conditions":2827,"interventions":2829},"NCT00696332","Talampanel for Amyotrophic Lateral Sclerosis (ALS)",[39],"2010-04",559,[2828],"ALS",[2751,2751],{"trials":2831,"activeCount":8},[],{"trials":2833,"activeCount":8},[],{"trials":2835,"activeCount":8},[],{"intervention":2837,"totalTrials":34,"cells":2838},"Omacetaxine mepesuccinate",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2851,"PHASE3":2883,"PHASE4":2885,"NA":2887},{"trials":2840,"activeCount":8},[],{"trials":2842,"activeCount":8},[2843],{"nctId":2844,"briefTitle":2845,"status":70,"phases":2846,"primaryCompletion":926,"completion":114,"start":399,"enrollment":1047,"conditions":2847,"interventions":2849},"NCT01844869","An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate",[38],[2848,33],"Hematologic Malignancies",[2850],"omacetaxine mepesuccinate",{"trials":2852,"activeCount":8},[2853,2864,2874],{"nctId":2854,"briefTitle":2855,"status":58,"phases":2856,"primaryCompletion":2857,"completion":2858,"start":2859,"enrollment":2860,"conditions":2861,"interventions":2863},"NCT02078960","A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)",[38,39],"2017-07-06","2017-11-27","2014-10-09",10,[2862],"Chronic Myeloid Leukemia",[2837],{"nctId":2865,"briefTitle":2866,"status":70,"phases":2867,"primaryCompletion":2868,"completion":2869,"start":2870,"enrollment":2871,"conditions":2872,"interventions":2873},"NCT00462943","Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML",[39],"2009-08-04","2013-06-27","2007-03-07",100,[2862],[2837],{"nctId":2875,"briefTitle":2876,"status":70,"phases":2877,"primaryCompletion":2878,"completion":2879,"start":2880,"enrollment":2612,"conditions":2881,"interventions":2882},"NCT00375219","Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation",[39],"2010-03-23","2013-06-28","2006-09-20",[2862],[2837],{"trials":2884,"activeCount":8},[],{"trials":2886,"activeCount":8},[],{"trials":2888,"activeCount":8},[],{"intervention":2890,"totalTrials":248,"cells":2891},"TV-45070",{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2903,"PHASE3":2926,"PHASE4":2928,"NA":2930},{"trials":2893,"activeCount":8},[],{"trials":2895,"activeCount":8},[2896],{"nctId":2897,"briefTitle":2898,"status":70,"phases":2899,"primaryCompletion":785,"completion":1263,"start":1194,"enrollment":2900,"conditions":2901,"interventions":2902},"NCT02215941","Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers",[38],45,[28],[2890],{"trials":2904,"activeCount":8},[2905,2916],{"nctId":2906,"briefTitle":2907,"status":70,"phases":2908,"primaryCompletion":2909,"completion":2910,"start":2911,"enrollment":2912,"conditions":2913,"interventions":2915},"NCT02068599","A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee",[39],"2015-04-06","2015-05-04","2014-04-14",389,[2914],"Osteoarthritis of the Knee",[2890],{"nctId":2917,"briefTitle":2918,"status":70,"phases":2919,"primaryCompletion":2920,"completion":2920,"start":2921,"enrollment":2922,"conditions":2923,"interventions":2925},"NCT02365636","A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)",[39],"2017-05-09","2015-02-26",300,[2924],"Postherpetic Neuralgia",[2890],{"trials":2927,"activeCount":8},[],{"trials":2929,"activeCount":8},[],{"trials":2931,"activeCount":8},[],{"intervention":1340,"totalTrials":433,"cells":2933},{"EARLY_PHASE1":2934,"PHASE1":2936,"PHASE2":2942,"PHASE3":2948,"PHASE4":2950,"NA":2952},{"trials":2935,"activeCount":8},[],{"trials":2937,"activeCount":8},[2938],{"nctId":1333,"briefTitle":1334,"status":70,"phases":2939,"primaryCompletion":123,"completion":410,"start":1336,"enrollment":1337,"conditions":2940,"interventions":2941},[38],[14],[1326,1340],{"trials":2943,"activeCount":8},[2944],{"nctId":1344,"briefTitle":1345,"status":70,"phases":2945,"primaryCompletion":198,"completion":198,"start":1347,"enrollment":1003,"conditions":2946,"interventions":2947},[39],[14],[1326,1340],{"trials":2949,"activeCount":8},[],{"trials":2951,"activeCount":8},[],{"trials":2953,"activeCount":8},[],{"intervention":2955,"totalTrials":433,"cells":2956},"LBR-101 High Dose",{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2961,"PHASE3":2984,"PHASE4":2986,"NA":2988},{"trials":2958,"activeCount":8},[],{"trials":2960,"activeCount":8},[],{"trials":2962,"activeCount":8},[2963,2975],{"nctId":2964,"briefTitle":2965,"status":70,"phases":2966,"primaryCompletion":2967,"completion":2968,"start":2969,"enrollment":2970,"conditions":2971,"interventions":2973},"NCT02021773","Assessment of LBR-101 In Chronic Migraine",[39],"2015-02-28","2015-03-31","2014-01-31",264,[2972],"Chronic Migraine",[2955,2974],"LBR-101 Low Dose",{"nctId":2976,"briefTitle":2977,"status":70,"phases":2978,"primaryCompletion":2979,"completion":2968,"start":2969,"enrollment":2980,"conditions":2981,"interventions":2983},"NCT02025556","A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine",[39],"2015-01-31",297,[2982],"Episodic Migraine Headache",[2955,2974],{"trials":2985,"activeCount":8},[],{"trials":2987,"activeCount":8},[],{"trials":2989,"activeCount":8},[],{"intervention":2974,"totalTrials":433,"cells":2991},{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":3006,"PHASE4":3008,"NA":3010},{"trials":2993,"activeCount":8},[],{"trials":2995,"activeCount":8},[],{"trials":2997,"activeCount":8},[2998,3002],{"nctId":2964,"briefTitle":2965,"status":70,"phases":2999,"primaryCompletion":2967,"completion":2968,"start":2969,"enrollment":2970,"conditions":3000,"interventions":3001},[39],[2972],[2955,2974],{"nctId":2976,"briefTitle":2977,"status":70,"phases":3003,"primaryCompletion":2979,"completion":2968,"start":2969,"enrollment":2980,"conditions":3004,"interventions":3005},[39],[2982],[2955,2974],{"trials":3007,"activeCount":8},[],{"trials":3009,"activeCount":8},[],{"trials":3011,"activeCount":8},[],{"intervention":3013,"totalTrials":433,"cells":3014},"TP-38",{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3039,"PHASE4":3041,"NA":3043},{"trials":3016,"activeCount":8},[],{"trials":3018,"activeCount":8},[],{"trials":3020,"activeCount":8},[3021,3031],{"nctId":3022,"briefTitle":3023,"status":70,"phases":3024,"primaryCompletion":3025,"completion":3026,"start":3027,"enrollment":3028,"conditions":3029,"interventions":3030},"NCT00104091","Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors",[39],"2007-04","2007-06","2004-12",56,[2794],[3013],{"nctId":3032,"briefTitle":3023,"status":70,"phases":3033,"primaryCompletion":2781,"completion":515,"start":3034,"enrollment":3028,"conditions":3035,"interventions":3037},"NCT00071539",[39],"2003-10",[3036],"Recurrent Glioblastoma Multiforme",[3013,3038],"TP38",{"trials":3040,"activeCount":8},[],{"trials":3042,"activeCount":8},[],{"trials":3044,"activeCount":8},[],{"intervention":3046,"totalTrials":433,"cells":3047},"TEV-48574",{"EARLY_PHASE1":3048,"PHASE1":3050,"PHASE2":3052,"PHASE3":3074,"PHASE4":3076,"NA":3078},{"trials":3049,"activeCount":8},[],{"trials":3051,"activeCount":8},[],{"trials":3053,"activeCount":8},[3054,3063],{"nctId":3055,"briefTitle":3056,"status":58,"phases":3057,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":3060,"conditions":3061,"interventions":3062},"NCT04545385","A Study to Test if TEV-48574 is Effective in Relieving Asthma",[39],"2022-01-17","2020-10-07",65,[14],[3046],{"nctId":3064,"briefTitle":3065,"status":70,"phases":3066,"primaryCompletion":3067,"completion":3067,"start":3068,"enrollment":3069,"conditions":3070,"interventions":3073},"NCT05499130","A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease",[39],"2024-11-12","2022-09-30",290,[3071,3072],"Crohn Disease","Colitis, Ulcerative",[3046],{"trials":3075,"activeCount":8},[],{"trials":3077,"activeCount":8},[],{"trials":3079,"activeCount":8},[],{"intervention":3081,"totalTrials":433,"cells":3082},"Desogestrel\u002Fethinyl estradiol and ethinyl estradiol",{"EARLY_PHASE1":3083,"PHASE1":3085,"PHASE2":3102,"PHASE3":3116,"PHASE4":3118,"NA":3120},{"trials":3084,"activeCount":8},[],{"trials":3086,"activeCount":8},[3087],{"nctId":3088,"briefTitle":3089,"status":70,"phases":3090,"primaryCompletion":355,"completion":355,"start":3091,"enrollment":3092,"conditions":3093,"interventions":3099},"NCT01291004","A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives",[38],"2011-01-31",206,[3094,3095,3096,3097,3098],"Follicle Development","Ovarian Follicle","Follicle Count","Follicle Size","Oral Contraceptive",[3081,3100,3101],"28-day drospirenone oral contraceptive","28-day levonorgestrel oral contraceptive",{"trials":3103,"activeCount":8},[3104],{"nctId":3105,"briefTitle":3106,"status":70,"phases":3107,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":3111,"interventions":3113},"NCT01388491","A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women",[39],"2012-09-30","2011-10-31",293,[3112,3098],"Hemostasis",[3114,3115],"desogestrel\u002Fethinyl estradiol and ethinyl estradiol","desogestrel\u002Fethinyl estradiol",{"trials":3117,"activeCount":8},[],{"trials":3119,"activeCount":8},[],{"trials":3121,"activeCount":8},[],{"intervention":3123,"totalTrials":433,"cells":3124},"Laquinimod 0.6",{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3129,"PHASE3":3148,"PHASE4":3150,"NA":3152},{"trials":3126,"activeCount":8},[],{"trials":3128,"activeCount":8},[],{"trials":3130,"activeCount":8},[3131,3138],{"nctId":3132,"briefTitle":3133,"status":845,"phases":3134,"primaryCompletion":82,"completion":847,"start":167,"enrollment":8,"conditions":3135,"interventions":3136},"NCT01404117","A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability",[39],[868],[3123,3137],"Laquinimod 1.2",{"nctId":3139,"briefTitle":3140,"status":70,"phases":3141,"primaryCompletion":514,"completion":1451,"start":3142,"enrollment":3143,"conditions":3144,"interventions":3145},"NCT00349193","A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod",[39],"2005-03",306,[20],[3146,3147],"laquinimod 0.3","laquinimod 0.6",{"trials":3149,"activeCount":8},[],{"trials":3151,"activeCount":8},[],{"trials":3153,"activeCount":8},[],{"intervention":3155,"totalTrials":538,"cells":3156},"TEV-53275 Dose A",{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3161,"PHASE3":3173,"PHASE4":3175,"NA":3177},{"trials":3158,"activeCount":8},[],{"trials":3160,"activeCount":8},[],{"trials":3162,"activeCount":8},[3163],{"nctId":3164,"briefTitle":3165,"status":58,"phases":3166,"primaryCompletion":3167,"completion":3167,"start":3168,"enrollment":3169,"conditions":3170,"interventions":3171},"NCT04847674","A Study to Test if TEV-53275 is Effective in Relieving Asthma",[39],"2022-04-28","2021-05-04",97,[14],[3155,3172],"TEV-53275 Dose B",{"trials":3174,"activeCount":8},[],{"trials":3176,"activeCount":8},[],{"trials":3178,"activeCount":8},[],{"intervention":3172,"totalTrials":538,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3182,"activeCount":8},[],{"trials":3184,"activeCount":8},[],{"trials":3186,"activeCount":8},[3187],{"nctId":3164,"briefTitle":3165,"status":58,"phases":3188,"primaryCompletion":3167,"completion":3167,"start":3168,"enrollment":3169,"conditions":3189,"interventions":3190},[39],[14],[3155,3172],{"trials":3192,"activeCount":8},[],{"trials":3194,"activeCount":8},[],{"trials":3196,"activeCount":8},[],{"intervention":3198,"totalTrials":538,"cells":3199},"Nebulized IVX-0142",{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3204,"PHASE3":3213,"PHASE4":3215,"NA":3217},{"trials":3201,"activeCount":8},[],{"trials":3203,"activeCount":8},[],{"trials":3205,"activeCount":8},[3206],{"nctId":3207,"briefTitle":3208,"status":70,"phases":3209,"primaryCompletion":2804,"completion":2781,"start":3210,"enrollment":1337,"conditions":3211,"interventions":3212},"NCT00232999","Efficacy\u002FSafety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma",[39],"2005-10",[14],[3198],{"trials":3214,"activeCount":8},[],{"trials":3216,"activeCount":8},[],{"trials":3218,"activeCount":8},[],{"intervention":3220,"totalTrials":538,"cells":3221},"CEP-18770",{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3240,"PHASE4":3242,"NA":3244},{"trials":3223,"activeCount":8},[],{"trials":3225,"activeCount":8},[],{"trials":3227,"activeCount":8},[3228],{"nctId":3229,"briefTitle":3230,"status":70,"phases":3231,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":3234,"conditions":3235,"interventions":3237},"NCT01348919","Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma",[38,39],"2013-03-14","2011-08-03",11,[3236],"Multiple Myeloma",[3220,3238,3239],"Lenalidomide","Dexamethasone",{"trials":3241,"activeCount":8},[],{"trials":3243,"activeCount":8},[],{"trials":3245,"activeCount":8},[],{"intervention":3238,"totalTrials":538,"cells":3247},{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3252,"PHASE3":3258,"PHASE4":3260,"NA":3262},{"trials":3249,"activeCount":8},[],{"trials":3251,"activeCount":8},[],{"trials":3253,"activeCount":8},[3254],{"nctId":3229,"briefTitle":3230,"status":70,"phases":3255,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":3234,"conditions":3256,"interventions":3257},[38,39],[3236],[3220,3238,3239],{"trials":3259,"activeCount":8},[],{"trials":3261,"activeCount":8},[],{"trials":3263,"activeCount":8},[],{"intervention":3239,"totalTrials":538,"cells":3265},{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3276,"PHASE4":3278,"NA":3280},{"trials":3267,"activeCount":8},[],{"trials":3269,"activeCount":8},[],{"trials":3271,"activeCount":8},[3272],{"nctId":3229,"briefTitle":3230,"status":70,"phases":3273,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":3234,"conditions":3274,"interventions":3275},[38,39],[3236],[3220,3238,3239],{"trials":3277,"activeCount":8},[],{"trials":3279,"activeCount":8},[],{"trials":3281,"activeCount":8},[],{"intervention":3283,"totalTrials":538,"cells":3284},"edratide",{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3299,"PHASE4":3301,"NA":3303},{"trials":3286,"activeCount":8},[],{"trials":3288,"activeCount":8},[],{"trials":3290,"activeCount":8},[3291],{"nctId":3292,"briefTitle":3293,"status":58,"phases":3294,"primaryCompletion":2813,"completion":2813,"start":3295,"enrollment":951,"conditions":3296,"interventions":3298},"NCT00203151","A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus",[39],"2005-07",[3297],"Systemic Lupus Erythematosus",[3283],{"trials":3300,"activeCount":8},[],{"trials":3302,"activeCount":8},[],{"trials":3304,"activeCount":8},[],{"intervention":3306,"totalTrials":538,"cells":3307},"CEP-9722",{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3312,"PHASE3":3322,"PHASE4":3324,"NA":3326},{"trials":3309,"activeCount":8},[],{"trials":3311,"activeCount":8},[],{"trials":3313,"activeCount":8},[3314],{"nctId":3315,"briefTitle":3316,"status":58,"phases":3317,"primaryCompletion":3318,"completion":3318,"start":3319,"enrollment":2900,"conditions":3320,"interventions":3321},"NCT01311713","Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors",[38,39],"2013-10-16","2011-05-02",[33],[3306],{"trials":3323,"activeCount":8},[],{"trials":3325,"activeCount":8},[],{"trials":3327,"activeCount":8},[],{"intervention":452,"totalTrials":538,"cells":3329},{"EARLY_PHASE1":3330,"PHASE1":3332,"PHASE2":3334,"PHASE3":3340,"PHASE4":3342,"NA":3344},{"trials":3331,"activeCount":8},[],{"trials":3333,"activeCount":8},[],{"trials":3335,"activeCount":8},[3336],{"nctId":442,"briefTitle":443,"status":70,"phases":3337,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":3338,"interventions":3339},[39],[449],[451,432,452,453],{"trials":3341,"activeCount":8},[],{"trials":3343,"activeCount":8},[],{"trials":3345,"activeCount":8},[],{"intervention":453,"totalTrials":538,"cells":3347},{"EARLY_PHASE1":3348,"PHASE1":3350,"PHASE2":3352,"PHASE3":3358,"PHASE4":3360,"NA":3362},{"trials":3349,"activeCount":8},[],{"trials":3351,"activeCount":8},[],{"trials":3353,"activeCount":8},[3354],{"nctId":442,"briefTitle":443,"status":70,"phases":3355,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":3356,"interventions":3357},[39],[449],[451,432,452,453],{"trials":3359,"activeCount":8},[],{"trials":3361,"activeCount":8},[],{"trials":3363,"activeCount":8},[],{"intervention":3365,"totalTrials":538,"cells":3366},"Tiotropium HFA BAI 4.5 mcg",{"EARLY_PHASE1":3367,"PHASE1":3369,"PHASE2":3371,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3368,"activeCount":8},[],{"trials":3370,"activeCount":8},[],{"trials":3372,"activeCount":8},[3373],{"nctId":3374,"briefTitle":3375,"status":70,"phases":3376,"primaryCompletion":399,"completion":123,"start":1002,"enrollment":3377,"conditions":3378,"interventions":3380},"NCT01785433","To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[38,39],36,[3379],"COPD",[3365,3381,3382,3383],"Tiotropium HFA BAI 9.0 mcg","SPIRIVA® HandiHaler® 18 mcg\u002Fday","Spiriva® Respimat® 5 mcg\u002Fday",{"trials":3385,"activeCount":8},[],{"trials":3387,"activeCount":8},[],{"trials":3389,"activeCount":8},[],{"intervention":3381,"totalTrials":538,"cells":3391},{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3402,"PHASE4":3404,"NA":3406},{"trials":3393,"activeCount":8},[],{"trials":3395,"activeCount":8},[],{"trials":3397,"activeCount":8},[3398],{"nctId":3374,"briefTitle":3375,"status":70,"phases":3399,"primaryCompletion":399,"completion":123,"start":1002,"enrollment":3377,"conditions":3400,"interventions":3401},[38,39],[3379],[3365,3381,3382,3383],{"trials":3403,"activeCount":8},[],{"trials":3405,"activeCount":8},[],{"trials":3407,"activeCount":8},[],{"intervention":3382,"totalTrials":538,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3414,"PHASE3":3420,"PHASE4":3422,"NA":3424},{"trials":3411,"activeCount":8},[],{"trials":3413,"activeCount":8},[],{"trials":3415,"activeCount":8},[3416],{"nctId":3374,"briefTitle":3375,"status":70,"phases":3417,"primaryCompletion":399,"completion":123,"start":1002,"enrollment":3377,"conditions":3418,"interventions":3419},[38,39],[3379],[3365,3381,3382,3383],{"trials":3421,"activeCount":8},[],{"trials":3423,"activeCount":8},[],{"trials":3425,"activeCount":8},[],{"intervention":3383,"totalTrials":538,"cells":3427},{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3429,"activeCount":8},[],{"trials":3431,"activeCount":8},[],{"trials":3433,"activeCount":8},[3434],{"nctId":3374,"briefTitle":3375,"status":70,"phases":3435,"primaryCompletion":399,"completion":123,"start":1002,"enrollment":3377,"conditions":3436,"interventions":3437},[38,39],[3379],[3365,3381,3382,3383],{"trials":3439,"activeCount":8},[],{"trials":3441,"activeCount":8},[],{"trials":3443,"activeCount":8},[],{"intervention":1432,"totalTrials":538,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3456,"PHASE4":3458,"NA":3460},{"trials":3447,"activeCount":8},[],{"trials":3449,"activeCount":8},[],{"trials":3451,"activeCount":8},[3452],{"nctId":1425,"briefTitle":1426,"status":70,"phases":3453,"primaryCompletion":231,"completion":1428,"start":1429,"enrollment":787,"conditions":3454,"interventions":3455},[39],[20],[1416,1432],{"trials":3457,"activeCount":8},[],{"trials":3459,"activeCount":8},[],{"trials":3461,"activeCount":8},[],{"intervention":3463,"totalTrials":538,"cells":3464},"TV-1380 150 mg",{"EARLY_PHASE1":3465,"PHASE1":3467,"PHASE2":3469,"PHASE3":3480,"PHASE4":3482,"NA":3484},{"trials":3466,"activeCount":8},[],{"trials":3468,"activeCount":8},[],{"trials":3470,"activeCount":8},[3471],{"nctId":3472,"briefTitle":3473,"status":70,"phases":3474,"primaryCompletion":784,"completion":3475,"start":311,"enrollment":6,"conditions":3476,"interventions":3478},"NCT01887366","Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects",[39],"2014-10",[3477],"Cocaine Addiction",[3463,3479],"TV-1380 300 mg",{"trials":3481,"activeCount":8},[],{"trials":3483,"activeCount":8},[],{"trials":3485,"activeCount":8},[],{"intervention":3479,"totalTrials":538,"cells":3487},{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3498,"PHASE4":3500,"NA":3502},{"trials":3489,"activeCount":8},[],{"trials":3491,"activeCount":8},[],{"trials":3493,"activeCount":8},[3494],{"nctId":3472,"briefTitle":3473,"status":70,"phases":3495,"primaryCompletion":784,"completion":3475,"start":311,"enrollment":6,"conditions":3496,"interventions":3497},[39],[3477],[3463,3479],{"trials":3499,"activeCount":8},[],{"trials":3501,"activeCount":8},[],{"trials":3503,"activeCount":8},[],{"intervention":3505,"totalTrials":538,"cells":3506},"Glatiramer Acetate, N-Acetylcysteine",{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3511,"PHASE3":3521,"PHASE4":3523,"NA":3525},{"trials":3508,"activeCount":8},[],{"trials":3510,"activeCount":8},[],{"trials":3512,"activeCount":8},[3513],{"nctId":3514,"briefTitle":3515,"status":70,"phases":3516,"primaryCompletion":1451,"completion":3517,"start":3027,"enrollment":3518,"conditions":3519,"interventions":3520},"NCT00203099","Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine",[39],"2008-06",18,[518],[3505],{"trials":3522,"activeCount":8},[],{"trials":3524,"activeCount":8},[],{"trials":3526,"activeCount":8},[],{"intervention":3528,"totalTrials":538,"cells":3529},"Tiotropium HFA BAI 5 mcg",{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3534,"PHASE3":3543,"PHASE4":3545,"NA":3547},{"trials":3531,"activeCount":8},[],{"trials":3533,"activeCount":8},[],{"trials":3535,"activeCount":8},[3536],{"nctId":3537,"briefTitle":3538,"status":845,"phases":3539,"primaryCompletion":1194,"completion":1194,"start":1194,"enrollment":8,"conditions":3540,"interventions":3541},"NCT02203474","A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease",[39],[1759,3379],[3528,3542],"Tiotropium 18 mcg",{"trials":3544,"activeCount":8},[],{"trials":3546,"activeCount":8},[],{"trials":3548,"activeCount":8},[],{"intervention":3542,"totalTrials":538,"cells":3550},{"EARLY_PHASE1":3551,"PHASE1":3553,"PHASE2":3555,"PHASE3":3561,"PHASE4":3563,"NA":3565},{"trials":3552,"activeCount":8},[],{"trials":3554,"activeCount":8},[],{"trials":3556,"activeCount":8},[3557],{"nctId":3537,"briefTitle":3538,"status":845,"phases":3558,"primaryCompletion":1194,"completion":1194,"start":1194,"enrollment":8,"conditions":3559,"interventions":3560},[39],[1759,3379],[3528,3542],{"trials":3562,"activeCount":8},[],{"trials":3564,"activeCount":8},[],{"trials":3566,"activeCount":8},[],{"intervention":3568,"totalTrials":538,"cells":3569},"Beclomethasone dipropionate HFA Nasal Aerosol",{"EARLY_PHASE1":3570,"PHASE1":3572,"PHASE2":3574,"PHASE3":3585,"PHASE4":3587,"NA":3589},{"trials":3571,"activeCount":8},[],{"trials":3573,"activeCount":8},[],{"trials":3575,"activeCount":8},[3576],{"nctId":3577,"briefTitle":3578,"status":70,"phases":3579,"primaryCompletion":230,"completion":230,"start":3580,"enrollment":3581,"conditions":3582,"interventions":3584},"NCT00854360","Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR",[39],"2009-03",487,[953,3583],"Hayfever",[3568],{"trials":3586,"activeCount":8},[],{"trials":3588,"activeCount":8},[],{"trials":3590,"activeCount":8},[],{"intervention":1685,"totalTrials":538,"cells":3592},{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3603,"PHASE4":3605,"NA":3607},{"trials":3594,"activeCount":8},[],{"trials":3596,"activeCount":8},[],{"trials":3598,"activeCount":8},[3599],{"nctId":1678,"briefTitle":1679,"status":845,"phases":3600,"primaryCompletion":1681,"completion":1682,"start":784,"enrollment":8,"conditions":3601,"interventions":3602},[39],[33],[1385,1685],{"trials":3604,"activeCount":8},[],{"trials":3606,"activeCount":8},[],{"trials":3608,"activeCount":8},[],{"intervention":3038,"totalTrials":538,"cells":3610},{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3615,"PHASE3":3621,"PHASE4":3623,"NA":3625},{"trials":3612,"activeCount":8},[],{"trials":3614,"activeCount":8},[],{"trials":3616,"activeCount":8},[3617],{"nctId":3032,"briefTitle":3023,"status":70,"phases":3618,"primaryCompletion":2781,"completion":515,"start":3034,"enrollment":3028,"conditions":3619,"interventions":3620},[39],[3036],[3013,3038],{"trials":3622,"activeCount":8},[],{"trials":3624,"activeCount":8},[],{"trials":3626,"activeCount":8},[],{"intervention":1443,"totalTrials":538,"cells":3628},{"EARLY_PHASE1":3629,"PHASE1":3631,"PHASE2":3633,"PHASE3":3639,"PHASE4":3641,"NA":3643},{"trials":3630,"activeCount":8},[],{"trials":3632,"activeCount":8},[],{"trials":3634,"activeCount":8},[3635],{"nctId":1434,"briefTitle":1435,"status":70,"phases":3636,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":1439,"conditions":3637,"interventions":3638},[39],[1441],[1416,1443],{"trials":3640,"activeCount":8},[],{"trials":3642,"activeCount":8},[],{"trials":3644,"activeCount":8},[],{"intervention":3646,"totalTrials":538,"cells":3647},"etiprednol dicloacetate",{"EARLY_PHASE1":3648,"PHASE1":3650,"PHASE2":3652,"PHASE3":3661,"PHASE4":3663,"NA":3665},{"trials":3649,"activeCount":8},[],{"trials":3651,"activeCount":8},[],{"trials":3653,"activeCount":8},[3654],{"nctId":3655,"briefTitle":3656,"status":70,"phases":3657,"primaryCompletion":424,"completion":424,"start":3658,"conditions":3659,"interventions":3660},"NCT00035503","Multicenter Trial For Patients With Acute Crohn's Disease",[39],"2002-01-31",[813],[3646],{"trials":3662,"activeCount":8},[],{"trials":3664,"activeCount":8},[],{"trials":3666,"activeCount":8},[],{"intervention":3115,"totalTrials":538,"cells":3668},{"EARLY_PHASE1":3669,"PHASE1":3671,"PHASE2":3673,"PHASE3":3679,"PHASE4":3681,"NA":3683},{"trials":3670,"activeCount":8},[],{"trials":3672,"activeCount":8},[],{"trials":3674,"activeCount":8},[3675],{"nctId":3105,"briefTitle":3106,"status":70,"phases":3676,"primaryCompletion":3108,"completion":3108,"start":3109,"enrollment":3110,"conditions":3677,"interventions":3678},[39],[3112,3098],[3114,3115],{"trials":3680,"activeCount":8},[],{"trials":3682,"activeCount":8},[],{"trials":3684,"activeCount":8},[],{"intervention":3137,"totalTrials":538,"cells":3686},{"EARLY_PHASE1":3687,"PHASE1":3689,"PHASE2":3691,"PHASE3":3697,"PHASE4":3699,"NA":3701},{"trials":3688,"activeCount":8},[],{"trials":3690,"activeCount":8},[],{"trials":3692,"activeCount":8},[3693],{"nctId":3132,"briefTitle":3133,"status":845,"phases":3694,"primaryCompletion":82,"completion":847,"start":167,"enrollment":8,"conditions":3695,"interventions":3696},[39],[868],[3123,3137],{"trials":3698,"activeCount":8},[],{"trials":3700,"activeCount":8},[],{"trials":3702,"activeCount":8},[],{"intervention":1479,"totalTrials":538,"cells":3704},{"EARLY_PHASE1":3705,"PHASE1":3707,"PHASE2":3709,"PHASE3":3715,"PHASE4":3717,"NA":3719},{"trials":3706,"activeCount":8},[],{"trials":3708,"activeCount":8},[],{"trials":3710,"activeCount":8},[3711],{"nctId":1470,"briefTitle":1471,"status":70,"phases":3712,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1475,"conditions":3713,"interventions":3714},[39],[1477],[1461,1479],{"trials":3716,"activeCount":8},[],{"trials":3718,"activeCount":8},[],{"trials":3720,"activeCount":8},[],{"intervention":1302,"totalTrials":538,"cells":3722},{"EARLY_PHASE1":3723,"PHASE1":3725,"PHASE2":3727,"PHASE3":3733,"PHASE4":3735,"NA":3737},{"trials":3724,"activeCount":8},[],{"trials":3726,"activeCount":8},[],{"trials":3728,"activeCount":8},[3729],{"nctId":1296,"briefTitle":1297,"status":70,"phases":3730,"primaryCompletion":410,"completion":410,"start":399,"enrollment":1299,"conditions":3731,"interventions":3732},[39],[14],[1287,1302],{"trials":3734,"activeCount":8},[],{"trials":3736,"activeCount":8},[],{"trials":3738,"activeCount":8},[],{"intervention":2807,"totalTrials":538,"cells":3740},{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3751,"PHASE4":3753,"NA":3755},{"trials":3742,"activeCount":8},[],{"trials":3744,"activeCount":8},[],{"trials":3746,"activeCount":8},[3747],{"nctId":2800,"briefTitle":2801,"status":70,"phases":3748,"primaryCompletion":2803,"completion":133,"start":2804,"enrollment":1003,"conditions":3749,"interventions":3750},[39],[2794],[2751,2807,2808],{"trials":3752,"activeCount":8},[],{"trials":3754,"activeCount":8},[],{"trials":3756,"activeCount":8},[],{"intervention":2808,"totalTrials":538,"cells":3758},{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3763,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3760,"activeCount":8},[],{"trials":3762,"activeCount":8},[],{"trials":3764,"activeCount":8},[3765],{"nctId":2800,"briefTitle":2801,"status":70,"phases":3766,"primaryCompletion":2803,"completion":133,"start":2804,"enrollment":1003,"conditions":3767,"interventions":3768},[39],[2794],[2751,2807,2808],{"trials":3770,"activeCount":8},[],{"trials":3772,"activeCount":8},[],{"trials":3774,"activeCount":8},[],{"intervention":520,"totalTrials":538,"cells":3776},{"EARLY_PHASE1":3777,"PHASE1":3779,"PHASE2":3781,"PHASE3":3787,"PHASE4":3789,"NA":3791},{"trials":3778,"activeCount":8},[],{"trials":3780,"activeCount":8},[],{"trials":3782,"activeCount":8},[3783],{"nctId":511,"briefTitle":512,"status":70,"phases":3784,"primaryCompletion":514,"completion":515,"start":516,"enrollment":178,"conditions":3785,"interventions":3786},[39],[518],[520,502],{"trials":3788,"activeCount":8},[],{"trials":3790,"activeCount":8},[],{"trials":3792,"activeCount":8},[],{"intervention":3794,"totalTrials":538,"cells":3795},"TEV-45478",{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3797,"activeCount":8},[],{"trials":3799,"activeCount":8},[],{"trials":3801,"activeCount":8},[3802],{"nctId":3803,"briefTitle":3804,"status":845,"phases":3805,"primaryCompletion":73,"completion":240,"start":3806,"enrollment":8,"conditions":3807,"interventions":3810},"NCT02769091","A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes",[39],"2016-09-30",[3808,3809],"Nonalcoholic Steatohepatitis","Type 2 Diabetes Mellitus",[3794],{"trials":3812,"activeCount":8},[],{"trials":3814,"activeCount":8},[],{"trials":3816,"activeCount":8},[],{"intervention":3818,"totalTrials":538,"cells":3819},"Albuterol HFA-BOI",{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3835,"PHASE4":3837,"NA":3839},{"trials":3821,"activeCount":8},[],{"trials":3823,"activeCount":8},[],{"trials":3825,"activeCount":8},[3826],{"nctId":3827,"briefTitle":3828,"status":70,"phases":3829,"primaryCompletion":3830,"completion":3830,"start":3831,"enrollment":1497,"conditions":3832,"interventions":3833},"NCT00054964","Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique",[39],"2003-08-31","2003-03-31",[14],[3818,3834],"Albuterol HFA-MDI",{"trials":3836,"activeCount":8},[],{"trials":3838,"activeCount":8},[],{"trials":3840,"activeCount":8},[],{"intervention":3834,"totalTrials":538,"cells":3842},{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3844,"activeCount":8},[],{"trials":3846,"activeCount":8},[],{"trials":3848,"activeCount":8},[3849],{"nctId":3827,"briefTitle":3828,"status":70,"phases":3850,"primaryCompletion":3830,"completion":3830,"start":3831,"enrollment":1497,"conditions":3851,"interventions":3852},[39],[14],[3818,3834],{"trials":3854,"activeCount":8},[],{"trials":3856,"activeCount":8},[],{"trials":3858,"activeCount":8},[],{"intervention":3146,"totalTrials":538,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3862,"activeCount":8},[],{"trials":3864,"activeCount":8},[],{"trials":3866,"activeCount":8},[3867],{"nctId":3139,"briefTitle":3140,"status":70,"phases":3868,"primaryCompletion":514,"completion":1451,"start":3142,"enrollment":3143,"conditions":3869,"interventions":3870},[39],[20],[3146,3147],{"trials":3872,"activeCount":8},[],{"trials":3874,"activeCount":8},[],{"trials":3876,"activeCount":8},[],{"intervention":3878,"totalTrials":538,"cells":3879},"Bronchodilator",{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3884,"PHASE3":3893,"PHASE4":3895,"NA":3897},{"trials":3881,"activeCount":8},[],{"trials":3883,"activeCount":8},[],{"trials":3885,"activeCount":8},[3886],{"nctId":3887,"briefTitle":3888,"status":70,"phases":3889,"primaryCompletion":489,"completion":489,"start":3890,"conditions":3891,"interventions":3892},"NCT00112411","Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics",[39],"2005-06-30",[14],[3878],{"trials":3894,"activeCount":8},[],{"trials":3896,"activeCount":8},[],{"trials":3898,"activeCount":8},[],{"intervention":3900,"totalTrials":433,"cells":3901},"TV-46046",{"EARLY_PHASE1":3902,"PHASE1":3904,"PHASE2":3928,"PHASE3":3930,"PHASE4":3932,"NA":3934},{"trials":3903,"activeCount":8},[],{"trials":3905,"activeCount":8},[3906,3917],{"nctId":3907,"briefTitle":3908,"status":70,"phases":3909,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":3912,"conditions":3913,"interventions":3914},"NCT03700658","A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046",[38],"2020-10-02","2019-01-15",27,[2211],[3900,3915,3916],"Depo-subQ 104","TV-46046 Placebo",{"nctId":3918,"briefTitle":3919,"status":70,"phases":3920,"primaryCompletion":3921,"completion":3922,"start":3923,"enrollment":3924,"conditions":3925,"interventions":3926},"NCT04682353","A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age",[38],"2022-07-11","2023-01-12","2020-12-14",60,[2211],[3900,3927],"Depo-subQ Provera",{"trials":3929,"activeCount":8},[],{"trials":3931,"activeCount":8},[],{"trials":3933,"activeCount":8},[],{"trials":3935,"activeCount":8},[],{"intervention":3937,"totalTrials":538,"cells":3938},"Armodafinil",{"EARLY_PHASE1":3939,"PHASE1":3941,"PHASE2":3951,"PHASE3":3953,"PHASE4":3955,"NA":3957},{"trials":3940,"activeCount":8},[],{"trials":3942,"activeCount":8},[3943],{"nctId":3944,"briefTitle":3945,"status":70,"phases":3946,"primaryCompletion":969,"completion":1682,"start":3947,"enrollment":787,"conditions":3948,"interventions":3950},"NCT01624480","Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy",[38],"2012-07",[3949],"Narcolepsy",[3937],{"trials":3952,"activeCount":8},[],{"trials":3954,"activeCount":8},[],{"trials":3956,"activeCount":8},[],{"trials":3958,"activeCount":8},[],{"intervention":3960,"totalTrials":538,"cells":3961},"Albuterol dry powder inhaler",{"EARLY_PHASE1":3962,"PHASE1":3964,"PHASE2":3974,"PHASE3":3976,"PHASE4":3978,"NA":3980},{"trials":3963,"activeCount":8},[],{"trials":3965,"activeCount":8},[3966],{"nctId":3967,"briefTitle":3968,"status":70,"phases":3969,"primaryCompletion":198,"completion":198,"start":2761,"enrollment":3970,"conditions":3971,"interventions":3972},"NCT01056159","A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)",[38],47,[14],[3960,3973],"Albuterol HFA MDI",{"trials":3975,"activeCount":8},[],{"trials":3977,"activeCount":8},[],{"trials":3979,"activeCount":8},[],{"trials":3981,"activeCount":8},[],{"intervention":3973,"totalTrials":538,"cells":3983},{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":3992,"PHASE3":3994,"PHASE4":3996,"NA":3998},{"trials":3985,"activeCount":8},[],{"trials":3987,"activeCount":8},[3988],{"nctId":3967,"briefTitle":3968,"status":70,"phases":3989,"primaryCompletion":198,"completion":198,"start":2761,"enrollment":3970,"conditions":3990,"interventions":3991},[38],[14],[3960,3973],{"trials":3993,"activeCount":8},[],{"trials":3995,"activeCount":8},[],{"trials":3997,"activeCount":8},[],{"trials":3999,"activeCount":8},[],{"intervention":4001,"totalTrials":538,"cells":4002},"a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).",{"EARLY_PHASE1":4003,"PHASE1":4005,"PHASE2":4014,"PHASE3":4016,"PHASE4":4018,"NA":4020},{"trials":4004,"activeCount":8},[],{"trials":4006,"activeCount":8},[4007],{"nctId":4008,"briefTitle":4009,"status":70,"phases":4010,"primaryCompletion":1002,"completion":1002,"start":1255,"enrollment":4011,"conditions":4012,"interventions":4013},"NCT01758978","A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet",[38],54,[2481],[4001],{"trials":4015,"activeCount":8},[],{"trials":4017,"activeCount":8},[],{"trials":4019,"activeCount":8},[],{"trials":4021,"activeCount":8},[],{"intervention":4023,"totalTrials":538,"cells":4024},"CEP-26401",{"EARLY_PHASE1":4025,"PHASE1":4027,"PHASE2":4038,"PHASE3":4040,"PHASE4":4042,"NA":4044},{"trials":4026,"activeCount":8},[],{"trials":4028,"activeCount":8},[4029],{"nctId":4030,"briefTitle":4031,"status":70,"phases":4032,"primaryCompletion":410,"completion":82,"start":123,"enrollment":787,"conditions":4033,"interventions":4035},"NCT01903824","Pharmacokinetics and Pharmacodynamics (PK\u002FPD) of CEP-26401 in Healthy Subjects",[38],[4034],"Cognitive Impairment",[4023,4036,4037],"donepezil hydrochloride","modafinil",{"trials":4039,"activeCount":8},[],{"trials":4041,"activeCount":8},[],{"trials":4043,"activeCount":8},[],{"trials":4045,"activeCount":8},[],{"intervention":4036,"totalTrials":538,"cells":4047},{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4056,"PHASE3":4058,"PHASE4":4060,"NA":4062},{"trials":4049,"activeCount":8},[],{"trials":4051,"activeCount":8},[4052],{"nctId":4030,"briefTitle":4031,"status":70,"phases":4053,"primaryCompletion":410,"completion":82,"start":123,"enrollment":787,"conditions":4054,"interventions":4055},[38],[4034],[4023,4036,4037],{"trials":4057,"activeCount":8},[],{"trials":4059,"activeCount":8},[],{"trials":4061,"activeCount":8},[],{"trials":4063,"activeCount":8},[],{"intervention":4037,"totalTrials":538,"cells":4065},{"EARLY_PHASE1":4066,"PHASE1":4068,"PHASE2":4074,"PHASE3":4076,"PHASE4":4078,"NA":4080},{"trials":4067,"activeCount":8},[],{"trials":4069,"activeCount":8},[4070],{"nctId":4030,"briefTitle":4031,"status":70,"phases":4071,"primaryCompletion":410,"completion":82,"start":123,"enrollment":787,"conditions":4072,"interventions":4073},[38],[4034],[4023,4036,4037],{"trials":4075,"activeCount":8},[],{"trials":4077,"activeCount":8},[],{"trials":4079,"activeCount":8},[],{"trials":4081,"activeCount":8},[],{"intervention":4083,"totalTrials":538,"cells":4084},"TEV-56286",{"EARLY_PHASE1":4085,"PHASE1":4087,"PHASE2":4098,"PHASE3":4100,"PHASE4":4102,"NA":4104},{"trials":4086,"activeCount":8},[],{"trials":4088,"activeCount":8},[4089],{"nctId":4090,"briefTitle":4091,"status":70,"phases":4092,"primaryCompletion":4093,"completion":4093,"start":4094,"enrollment":24,"conditions":4095,"interventions":4096},"NCT06627231","Mass Balance Clinical Trial With TEV-56286",[38],"2024-11-29","2024-10-08",[1640],[4083,4097],"[14C]-TEV-56286",{"trials":4099,"activeCount":8},[],{"trials":4101,"activeCount":8},[],{"trials":4103,"activeCount":8},[],{"trials":4105,"activeCount":8},[],{"intervention":4097,"totalTrials":538,"cells":4107},{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4116,"PHASE3":4118,"PHASE4":4120,"NA":4122},{"trials":4109,"activeCount":8},[],{"trials":4111,"activeCount":8},[4112],{"nctId":4090,"briefTitle":4091,"status":70,"phases":4113,"primaryCompletion":4093,"completion":4093,"start":4094,"enrollment":24,"conditions":4114,"interventions":4115},[38],[1640],[4083,4097],{"trials":4117,"activeCount":8},[],{"trials":4119,"activeCount":8},[],{"trials":4121,"activeCount":8},[],{"trials":4123,"activeCount":8},[],{"intervention":4125,"totalTrials":538,"cells":4126},"ADASUVE®",{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4140,"PHASE3":4142,"PHASE4":4144,"NA":4146},{"trials":4128,"activeCount":8},[],{"trials":4130,"activeCount":8},[4131],{"nctId":4132,"briefTitle":4133,"status":70,"phases":4134,"primaryCompletion":4135,"completion":4136,"start":1022,"enrollment":992,"conditions":4137,"interventions":4139},"NCT02184767","Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication",[38],"2015-03","2015-05",[4138],"BiPolar",[4125],{"trials":4141,"activeCount":8},[],{"trials":4143,"activeCount":8},[],{"trials":4145,"activeCount":8},[],{"trials":4147,"activeCount":8},[],{"intervention":2766,"totalTrials":538,"cells":4149},{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4158,"PHASE3":4160,"PHASE4":4162,"NA":4164},{"trials":4151,"activeCount":8},[],{"trials":4153,"activeCount":8},[4154],{"nctId":2758,"briefTitle":2759,"status":70,"phases":4155,"primaryCompletion":2761,"completion":1347,"start":2762,"enrollment":2763,"conditions":4156,"interventions":4157},[38],[1879],[2751,2766],{"trials":4159,"activeCount":8},[],{"trials":4161,"activeCount":8},[],{"trials":4163,"activeCount":8},[],{"trials":4165,"activeCount":8},[],{"intervention":4167,"totalTrials":538,"cells":4168},"Reslizumab IV",{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4182,"PHASE3":4184,"PHASE4":4186,"NA":4188},{"trials":4170,"activeCount":8},[],{"trials":4172,"activeCount":8},[4173],{"nctId":4174,"briefTitle":4175,"status":70,"phases":4176,"primaryCompletion":82,"completion":83,"start":311,"enrollment":4177,"conditions":4178,"interventions":4180},"NCT01990443","Absolute Bioavailability of Reslizumab in Healthy Subjects",[38],75,[4179],"Absolute Bioavailability",[4167,4181],"Reslizumab SC",{"trials":4183,"activeCount":8},[],{"trials":4185,"activeCount":8},[],{"trials":4187,"activeCount":8},[],{"trials":4189,"activeCount":8},[],{"intervention":4181,"totalTrials":538,"cells":4191},{"EARLY_PHASE1":4192,"PHASE1":4194,"PHASE2":4200,"PHASE3":4202,"PHASE4":4204,"NA":4206},{"trials":4193,"activeCount":8},[],{"trials":4195,"activeCount":8},[4196],{"nctId":4174,"briefTitle":4175,"status":70,"phases":4197,"primaryCompletion":82,"completion":83,"start":311,"enrollment":4177,"conditions":4198,"interventions":4199},[38],[4179],[4167,4181],{"trials":4201,"activeCount":8},[],{"trials":4203,"activeCount":8},[],{"trials":4205,"activeCount":8},[],{"trials":4207,"activeCount":8},[],{"intervention":264,"totalTrials":538,"cells":4209},{"EARLY_PHASE1":4210,"PHASE1":4212,"PHASE2":4218,"PHASE3":4220,"PHASE4":4222,"NA":4224},{"trials":4211,"activeCount":8},[],{"trials":4213,"activeCount":8},[4214],{"nctId":255,"briefTitle":256,"status":70,"phases":4215,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":4216,"interventions":4217},[38],[14],[264,265,247],{"trials":4219,"activeCount":8},[],{"trials":4221,"activeCount":8},[],{"trials":4223,"activeCount":8},[],{"trials":4225,"activeCount":8},[],{"intervention":265,"totalTrials":538,"cells":4227},{"EARLY_PHASE1":4228,"PHASE1":4230,"PHASE2":4236,"PHASE3":4238,"PHASE4":4240,"NA":4242},{"trials":4229,"activeCount":8},[],{"trials":4231,"activeCount":8},[4232],{"nctId":255,"briefTitle":256,"status":70,"phases":4233,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":4234,"interventions":4235},[38],[14],[264,265,247],{"trials":4237,"activeCount":8},[],{"trials":4239,"activeCount":8},[],{"trials":4241,"activeCount":8},[],{"trials":4243,"activeCount":8},[],{"intervention":3915,"totalTrials":538,"cells":4245},{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4254,"PHASE3":4256,"PHASE4":4258,"NA":4260},{"trials":4247,"activeCount":8},[],{"trials":4249,"activeCount":8},[4250],{"nctId":3907,"briefTitle":3908,"status":70,"phases":4251,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":3912,"conditions":4252,"interventions":4253},[38],[2211],[3900,3915,3916],{"trials":4255,"activeCount":8},[],{"trials":4257,"activeCount":8},[],{"trials":4259,"activeCount":8},[],{"trials":4261,"activeCount":8},[],{"intervention":3916,"totalTrials":538,"cells":4263},{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4272,"PHASE3":4274,"PHASE4":4276,"NA":4278},{"trials":4265,"activeCount":8},[],{"trials":4267,"activeCount":8},[4268],{"nctId":3907,"briefTitle":3908,"status":70,"phases":4269,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":3912,"conditions":4270,"interventions":4271},[38],[2211],[3900,3915,3916],{"trials":4273,"activeCount":8},[],{"trials":4275,"activeCount":8},[],{"trials":4277,"activeCount":8},[],{"trials":4279,"activeCount":8},[],{"intervention":4281,"totalTrials":538,"cells":4282},"BDP HFA Nasal Aerosol",{"EARLY_PHASE1":4283,"PHASE1":4285,"PHASE2":4296,"PHASE3":4298,"PHASE4":4300,"NA":4302},{"trials":4284,"activeCount":8},[],{"trials":4286,"activeCount":8},[4287],{"nctId":4288,"briefTitle":4289,"status":70,"phases":4290,"primaryCompletion":4291,"completion":4292,"start":3580,"enrollment":992,"conditions":4293,"interventions":4294},"NCT01537692","Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol",[38],"2009-04","2009-06",[1855],[4281,4281,4295],"BDP HFA Inhalation Aerosol",{"trials":4297,"activeCount":8},[],{"trials":4299,"activeCount":8},[],{"trials":4301,"activeCount":8},[],{"trials":4303,"activeCount":8},[],{"intervention":4295,"totalTrials":538,"cells":4305},{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4314,"PHASE3":4316,"PHASE4":4318,"NA":4320},{"trials":4307,"activeCount":8},[],{"trials":4309,"activeCount":8},[4310],{"nctId":4288,"briefTitle":4289,"status":70,"phases":4311,"primaryCompletion":4291,"completion":4292,"start":3580,"enrollment":992,"conditions":4312,"interventions":4313},[38],[1855],[4281,4281,4295],{"trials":4315,"activeCount":8},[],{"trials":4317,"activeCount":8},[],{"trials":4319,"activeCount":8},[],{"trials":4321,"activeCount":8},[],{"intervention":4323,"totalTrials":538,"cells":4324},"Talampanel (non-radiolabeled), [14C] Talampanel",{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4335,"PHASE3":4337,"PHASE4":4339,"NA":4341},{"trials":4326,"activeCount":8},[],{"trials":4328,"activeCount":8},[4329],{"nctId":4330,"briefTitle":4331,"status":58,"phases":4332,"primaryCompletion":186,"completion":186,"start":230,"enrollment":2860,"conditions":4333,"interventions":4334},"NCT00868361","A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel",[38],[1879],[4323],{"trials":4336,"activeCount":8},[],{"trials":4338,"activeCount":8},[],{"trials":4340,"activeCount":8},[],{"trials":4342,"activeCount":8},[],{"intervention":3100,"totalTrials":538,"cells":4344},{"EARLY_PHASE1":4345,"PHASE1":4347,"PHASE2":4353,"PHASE3":4355,"PHASE4":4357,"NA":4359},{"trials":4346,"activeCount":8},[],{"trials":4348,"activeCount":8},[4349],{"nctId":3088,"briefTitle":3089,"status":70,"phases":4350,"primaryCompletion":355,"completion":355,"start":3091,"enrollment":3092,"conditions":4351,"interventions":4352},[38],[3094,3095,3096,3097,3098],[3081,3100,3101],{"trials":4354,"activeCount":8},[],{"trials":4356,"activeCount":8},[],{"trials":4358,"activeCount":8},[],{"trials":4360,"activeCount":8},[],{"intervention":3101,"totalTrials":538,"cells":4362},{"EARLY_PHASE1":4363,"PHASE1":4365,"PHASE2":4371,"PHASE3":4373,"PHASE4":4375,"NA":4377},{"trials":4364,"activeCount":8},[],{"trials":4366,"activeCount":8},[4367],{"nctId":3088,"briefTitle":3089,"status":70,"phases":4368,"primaryCompletion":355,"completion":355,"start":3091,"enrollment":3092,"conditions":4369,"interventions":4370},[38],[3094,3095,3096,3097,3098],[3081,3100,3101],{"trials":4372,"activeCount":8},[],{"trials":4374,"activeCount":8},[],{"trials":4376,"activeCount":8},[],{"trials":4378,"activeCount":8},[],{"intervention":3927,"totalTrials":538,"cells":4380},{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4389,"PHASE3":4391,"PHASE4":4393,"NA":4395},{"trials":4382,"activeCount":8},[],{"trials":4384,"activeCount":8},[4385],{"nctId":3918,"briefTitle":3919,"status":70,"phases":4386,"primaryCompletion":3921,"completion":3922,"start":3923,"enrollment":3924,"conditions":4387,"interventions":4388},[38],[2211],[3900,3927],{"trials":4390,"activeCount":8},[],{"trials":4392,"activeCount":8},[],{"trials":4394,"activeCount":8},[],{"trials":4396,"activeCount":8},[],{"intervention":4398,"totalTrials":538,"cells":4399},"90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).",{"EARLY_PHASE1":4400,"PHASE1":4402,"PHASE2":4409,"PHASE3":4411,"PHASE4":4413,"NA":4415},{"trials":4401,"activeCount":8},[],{"trials":4403,"activeCount":8},[4404],{"nctId":4405,"briefTitle":4009,"status":70,"phases":4406,"primaryCompletion":1002,"completion":2001,"start":1002,"enrollment":4011,"conditions":4407,"interventions":4408},"NCT01769677",[38],[2481],[4398],{"trials":4410,"activeCount":8},[],{"trials":4412,"activeCount":8},[],{"trials":4414,"activeCount":8},[],{"trials":4416,"activeCount":8},[],{"intervention":4418,"totalTrials":538,"cells":4419},"TV-46046 - 400 mg\u002FmL",{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4434,"PHASE3":4436,"PHASE4":4438,"NA":4440},{"trials":4421,"activeCount":8},[],{"trials":4423,"activeCount":8},[4424],{"nctId":4425,"briefTitle":4426,"status":70,"phases":4427,"primaryCompletion":4428,"completion":4428,"start":4429,"enrollment":18,"conditions":4430,"interventions":4432},"NCT02817464","Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle",[38],"2018-12-03","2016-10-26",[4431,2211],"Pregnancy",[4418,4433],"TV-46046 - 200 mg\u002FmL",{"trials":4435,"activeCount":8},[],{"trials":4437,"activeCount":8},[],{"trials":4439,"activeCount":8},[],{"trials":4441,"activeCount":8},[],{"intervention":4433,"totalTrials":538,"cells":4443},{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4452,"PHASE3":4454,"PHASE4":4456,"NA":4458},{"trials":4445,"activeCount":8},[],{"trials":4447,"activeCount":8},[4448],{"nctId":4425,"briefTitle":4426,"status":70,"phases":4449,"primaryCompletion":4428,"completion":4428,"start":4429,"enrollment":18,"conditions":4450,"interventions":4451},[38],[4431,2211],[4418,4433],{"trials":4453,"activeCount":8},[],{"trials":4455,"activeCount":8},[],{"trials":4457,"activeCount":8},[],{"trials":4459,"activeCount":8},[],{"intervention":4461,"totalTrials":538,"cells":4462},"LBR-101 IV",{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4475,"PHASE3":4477,"PHASE4":4479,"NA":4481},{"trials":4464,"activeCount":8},[],{"trials":4466,"activeCount":8},[4467],{"nctId":4468,"briefTitle":4469,"status":70,"phases":4470,"primaryCompletion":926,"completion":114,"start":410,"enrollment":3377,"conditions":4471,"interventions":4473},"NCT01991509","Safety and Bioavailability of IV and SC LBR-101",[38],[4472],"Bioavailability and Pharmacokinetics",[4461,4474],"LBR-101 SC",{"trials":4476,"activeCount":8},[],{"trials":4478,"activeCount":8},[],{"trials":4480,"activeCount":8},[],{"trials":4482,"activeCount":8},[],{"intervention":4474,"totalTrials":538,"cells":4484},{"EARLY_PHASE1":4485,"PHASE1":4487,"PHASE2":4493,"PHASE3":4495,"PHASE4":4497,"NA":4499},{"trials":4486,"activeCount":8},[],{"trials":4488,"activeCount":8},[4489],{"nctId":4468,"briefTitle":4469,"status":70,"phases":4490,"primaryCompletion":926,"completion":114,"start":410,"enrollment":3377,"conditions":4491,"interventions":4492},[38],[4472],[4461,4474],{"trials":4494,"activeCount":8},[],{"trials":4496,"activeCount":8},[],{"trials":4498,"activeCount":8},[],{"trials":4500,"activeCount":8},[],{"intervention":4502,"totalTrials":538,"cells":4503},"TV-44749",{"EARLY_PHASE1":4504,"PHASE1":4506,"PHASE2":4517,"PHASE3":4519,"PHASE4":4521,"NA":4523},{"trials":4505,"activeCount":8},[],{"trials":4507,"activeCount":8},[4508],{"nctId":4509,"briefTitle":4510,"status":70,"phases":4511,"primaryCompletion":4512,"completion":4512,"start":4513,"enrollment":2321,"conditions":4514,"interventions":4515},"NCT06253546","Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia",[38],"2025-06-12","2024-03-28",[1715],[4502,4516],"Oral Olanzapine",{"trials":4518,"activeCount":8},[],{"trials":4520,"activeCount":8},[],{"trials":4522,"activeCount":8},[],{"trials":4524,"activeCount":8},[],{"intervention":4516,"totalTrials":538,"cells":4526},{"EARLY_PHASE1":4527,"PHASE1":4529,"PHASE2":4535,"PHASE3":4537,"PHASE4":4539,"NA":4541},{"trials":4528,"activeCount":8},[],{"trials":4530,"activeCount":8},[4531],{"nctId":4509,"briefTitle":4510,"status":70,"phases":4532,"primaryCompletion":4512,"completion":4512,"start":4513,"enrollment":2321,"conditions":4533,"interventions":4534},[38],[1715],[4502,4516],{"trials":4536,"activeCount":8},[],{"trials":4538,"activeCount":8},[],{"trials":4540,"activeCount":8},[],{"trials":4542,"activeCount":8},[],{"intervention":4544,"totalTrials":538,"cells":4545},"Progesterone vaginal ring,",{"EARLY_PHASE1":4546,"PHASE1":4548,"PHASE2":4556,"PHASE3":4558,"PHASE4":4560,"NA":4562},{"trials":4547,"activeCount":8},[],{"trials":4549,"activeCount":8},[4550],{"nctId":4551,"briefTitle":4552,"status":70,"phases":4553,"primaryCompletion":1022,"completion":1194,"start":786,"enrollment":3028,"conditions":4554,"interventions":4555},"NCT02092571","A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women",[38],[28],[4544],{"trials":4557,"activeCount":8},[],{"trials":4559,"activeCount":8},[],{"trials":4561,"activeCount":8},[],{"trials":4563,"activeCount":8},[],{"intervention":4565,"totalTrials":538,"cells":4566},"TV48108",{"EARLY_PHASE1":4567,"PHASE1":4569,"PHASE2":4579,"PHASE3":4581,"PHASE4":4583,"NA":4585},{"trials":4568,"activeCount":8},[],{"trials":4570,"activeCount":8},[4571],{"nctId":4572,"briefTitle":4573,"status":58,"phases":4574,"primaryCompletion":4575,"completion":4575,"start":4576,"enrollment":1299,"conditions":4577,"interventions":4578},"NCT02315144","An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients",[38],"2015-08","2015-04",[1759],[4565],{"trials":4580,"activeCount":8},[],{"trials":4582,"activeCount":8},[],{"trials":4584,"activeCount":8},[],{"trials":4586,"activeCount":8},[],{"intervention":4588,"totalTrials":538,"cells":4589},"TV46017",{"EARLY_PHASE1":4590,"PHASE1":4592,"PHASE2":4602,"PHASE3":4604,"PHASE4":4606,"NA":4608},{"trials":4591,"activeCount":8},[],{"trials":4593,"activeCount":8},[4594],{"nctId":4595,"briefTitle":4596,"status":58,"phases":4597,"primaryCompletion":4575,"completion":4575,"start":4135,"enrollment":4598,"conditions":4599,"interventions":4601},"NCT02315131","Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017",[38],53,[4600],"Chronic Obstructive Pulmonary Disease (COPD",[4588],{"trials":4603,"activeCount":8},[],{"trials":4605,"activeCount":8},[],{"trials":4607,"activeCount":8},[],{"trials":4609,"activeCount":8},[],{"intervention":1806,"totalTrials":538,"cells":4611},{"EARLY_PHASE1":4612,"PHASE1":4614,"PHASE2":4620,"PHASE3":4622,"PHASE4":4624,"NA":4626},{"trials":4613,"activeCount":8},[],{"trials":4615,"activeCount":8},[4616],{"nctId":1800,"briefTitle":1801,"status":70,"phases":4617,"primaryCompletion":399,"completion":132,"start":372,"enrollment":1265,"conditions":4618,"interventions":4619},[38],[1804],[1806,1807],{"trials":4621,"activeCount":8},[],{"trials":4623,"activeCount":8},[],{"trials":4625,"activeCount":8},[],{"trials":4627,"activeCount":8},[],{"intervention":4629,"totalTrials":538,"cells":4630},"TEV-48125 - 1",{"EARLY_PHASE1":4631,"PHASE1":4633,"PHASE2":4645,"PHASE3":4647,"PHASE4":4649,"NA":4651},{"trials":4632,"activeCount":8},[],{"trials":4634,"activeCount":8},[4635],{"nctId":4636,"briefTitle":4637,"status":70,"phases":4638,"primaryCompletion":4639,"completion":4640,"start":1079,"enrollment":312,"conditions":4641,"interventions":4642},"NCT02673567","To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125",[38],"2016-12-16","2017-02-10",[28],[4629,4643,4644],"TEV-48125 - 2","TEV-48125 - 3",{"trials":4646,"activeCount":8},[],{"trials":4648,"activeCount":8},[],{"trials":4650,"activeCount":8},[],{"trials":4652,"activeCount":8},[],{"intervention":4643,"totalTrials":538,"cells":4654},{"EARLY_PHASE1":4655,"PHASE1":4657,"PHASE2":4663,"PHASE3":4665,"PHASE4":4667,"NA":4669},{"trials":4656,"activeCount":8},[],{"trials":4658,"activeCount":8},[4659],{"nctId":4636,"briefTitle":4637,"status":70,"phases":4660,"primaryCompletion":4639,"completion":4640,"start":1079,"enrollment":312,"conditions":4661,"interventions":4662},[38],[28],[4629,4643,4644],{"trials":4664,"activeCount":8},[],{"trials":4666,"activeCount":8},[],{"trials":4668,"activeCount":8},[],{"trials":4670,"activeCount":8},[],{"intervention":4644,"totalTrials":538,"cells":4672},{"EARLY_PHASE1":4673,"PHASE1":4675,"PHASE2":4681,"PHASE3":4683,"PHASE4":4685,"NA":4687},{"trials":4674,"activeCount":8},[],{"trials":4676,"activeCount":8},[4677],{"nctId":4636,"briefTitle":4637,"status":70,"phases":4678,"primaryCompletion":4639,"completion":4640,"start":1079,"enrollment":312,"conditions":4679,"interventions":4680},[38],[28],[4629,4643,4644],{"trials":4682,"activeCount":8},[],{"trials":4684,"activeCount":8},[],{"trials":4686,"activeCount":8},[],{"trials":4688,"activeCount":8},[],{"intervention":4690,"totalTrials":538,"cells":4691},"CEP-37440",{"EARLY_PHASE1":4692,"PHASE1":4694,"PHASE2":4703,"PHASE3":4705,"PHASE4":4707,"NA":4709},{"trials":4693,"activeCount":8},[],{"trials":4695,"activeCount":8},[4696],{"nctId":4697,"briefTitle":4698,"status":70,"phases":4699,"primaryCompletion":969,"completion":1682,"start":399,"enrollment":4700,"conditions":4701,"interventions":4702},"NCT01922752","To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors",[38],32,[33],[4690],{"trials":4704,"activeCount":8},[],{"trials":4706,"activeCount":8},[],{"trials":4708,"activeCount":8},[],{"trials":4710,"activeCount":8},[],{"intervention":4712,"totalTrials":538,"cells":4713},"Treatment A: Fp MDPI",{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4727,"PHASE3":4729,"PHASE4":4731,"NA":4733},{"trials":4715,"activeCount":8},[],{"trials":4717,"activeCount":8},[4718],{"nctId":4719,"briefTitle":4720,"status":70,"phases":4721,"primaryCompletion":1021,"completion":969,"start":4136,"enrollment":464,"conditions":4722,"interventions":4723},"NCT02437604","Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate\u002FSalmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older",[38],[14],[4712,4724,4725,4726],"Treatment B: FS MDPI","Treatment C Flovent","Treatment D: Advair",{"trials":4728,"activeCount":8},[],{"trials":4730,"activeCount":8},[],{"trials":4732,"activeCount":8},[],{"trials":4734,"activeCount":8},[],{"intervention":4724,"totalTrials":538,"cells":4736},{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4745,"PHASE3":4747,"PHASE4":4749,"NA":4751},{"trials":4738,"activeCount":8},[],{"trials":4740,"activeCount":8},[4741],{"nctId":4719,"briefTitle":4720,"status":70,"phases":4742,"primaryCompletion":1021,"completion":969,"start":4136,"enrollment":464,"conditions":4743,"interventions":4744},[38],[14],[4712,4724,4725,4726],{"trials":4746,"activeCount":8},[],{"trials":4748,"activeCount":8},[],{"trials":4750,"activeCount":8},[],{"trials":4752,"activeCount":8},[],{"intervention":4725,"totalTrials":538,"cells":4754},{"EARLY_PHASE1":4755,"PHASE1":4757,"PHASE2":4763,"PHASE3":4765,"PHASE4":4767,"NA":4769},{"trials":4756,"activeCount":8},[],{"trials":4758,"activeCount":8},[4759],{"nctId":4719,"briefTitle":4720,"status":70,"phases":4760,"primaryCompletion":1021,"completion":969,"start":4136,"enrollment":464,"conditions":4761,"interventions":4762},[38],[14],[4712,4724,4725,4726],{"trials":4764,"activeCount":8},[],{"trials":4766,"activeCount":8},[],{"trials":4768,"activeCount":8},[],{"trials":4770,"activeCount":8},[],{"intervention":4726,"totalTrials":538,"cells":4772},{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4781,"PHASE3":4783,"PHASE4":4785,"NA":4787},{"trials":4774,"activeCount":8},[],{"trials":4776,"activeCount":8},[4777],{"nctId":4719,"briefTitle":4720,"status":70,"phases":4778,"primaryCompletion":1021,"completion":969,"start":4136,"enrollment":464,"conditions":4779,"interventions":4780},[38],[14],[4712,4724,4725,4726],{"trials":4782,"activeCount":8},[],{"trials":4784,"activeCount":8},[],{"trials":4786,"activeCount":8},[],{"trials":4788,"activeCount":8},[],{"intervention":995,"totalTrials":538,"cells":4790},{"EARLY_PHASE1":4791,"PHASE1":4793,"PHASE2":4799,"PHASE3":4801,"PHASE4":4803,"NA":4805},{"trials":4792,"activeCount":8},[],{"trials":4794,"activeCount":8},[4795],{"nctId":986,"briefTitle":987,"status":70,"phases":4796,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4797,"interventions":4798},[38],[14],[995,404],{"trials":4800,"activeCount":8},[],{"trials":4802,"activeCount":8},[],{"trials":4804,"activeCount":8},[],{"trials":4806,"activeCount":8},[],{"intervention":4808,"totalTrials":1337,"cells":4809},"Fremanezumab",{"EARLY_PHASE1":4810,"PHASE1":4812,"PHASE2":4814,"PHASE3":4847,"PHASE4":4944,"NA":4956},{"trials":4811,"activeCount":8},[],{"trials":4813,"activeCount":8},[],{"trials":4815,"activeCount":8},[4816,4826,4836],{"nctId":4817,"briefTitle":4818,"status":845,"phases":4819,"primaryCompletion":4820,"completion":4820,"start":4821,"enrollment":8,"conditions":4822,"interventions":4824},"NCT04447729","A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome",[39],"2022-02-10","2020-10-15",[4823],"Interstitial Cystitis",[4825],"fremanezumab",{"nctId":4827,"briefTitle":4828,"status":58,"phases":4829,"primaryCompletion":4830,"completion":4830,"start":4831,"enrollment":4832,"conditions":4833,"interventions":4835},"NCT03965091","A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia",[39],"2022-01-19","2019-07-31",189,[4834],"Fibromyalgia",[4808],{"nctId":4837,"briefTitle":4838,"status":70,"phases":4839,"primaryCompletion":4840,"completion":4841,"start":4842,"enrollment":4843,"conditions":4844,"interventions":4846},"NCT03347188","A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)",[39],"2020-03-13","2020-06-03","2017-12-18",87,[4845],"Post-Traumatic Headache",[4808],{"trials":4848,"activeCount":8},[4849,4858,4869,4879,4889,4898,4907,4916,4924,4934],{"nctId":4850,"briefTitle":4851,"status":70,"phases":4852,"primaryCompletion":4853,"completion":4853,"start":4854,"enrollment":4855,"conditions":4856,"interventions":4857},"NCT04458857","A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age",[40],"2024-03-13","2020-07-15",235,[23],[4808],{"nctId":4859,"briefTitle":4860,"status":70,"phases":4861,"primaryCompletion":4862,"completion":4863,"start":4864,"enrollment":4865,"conditions":4866,"interventions":4868},"NCT03308968","An Efficacy and Safety Study of Fremanezumab in Adults With Migraine",[40],"2018-10-02","2019-05-29","2017-10-13",838,[4867],"Migraine Prophylaxis",[4808],{"nctId":4870,"briefTitle":4871,"status":58,"phases":4872,"primaryCompletion":4873,"completion":4873,"start":4874,"enrollment":4875,"conditions":4876,"interventions":4878},"NCT02945046","A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)",[40],"2019-05-13","2017-01-19",169,[4877],"Episodic Cluster Headache",[4808],{"nctId":4880,"briefTitle":4881,"status":58,"phases":4882,"primaryCompletion":4883,"completion":4883,"start":4884,"enrollment":4885,"conditions":4886,"interventions":4888},"NCT03107052","A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache",[40],"2019-06-11","2017-04-27",275,[4887],"Cluster Headache",[4808],{"nctId":4890,"briefTitle":4891,"status":70,"phases":4892,"primaryCompletion":4893,"completion":4893,"start":4894,"enrollment":4895,"conditions":4896,"interventions":4897},"NCT02629861","Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine",[40],"2017-04-10","2016-03-23",875,[23],[4808],{"nctId":4899,"briefTitle":4900,"status":70,"phases":4901,"primaryCompletion":4902,"completion":4903,"start":3068,"enrollment":4904,"conditions":4905,"interventions":4906},"NCT05458011","A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine",[40],"2024-01-31","2024-06-13",365,[23],[4808],{"nctId":4908,"briefTitle":4909,"status":70,"phases":4910,"primaryCompletion":4911,"completion":4911,"start":4912,"enrollment":4913,"conditions":4914,"interventions":4915},"NCT02621931","Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine",[40],"2017-04-11","2016-03-22",1130,[23],[4808],{"nctId":4917,"briefTitle":4918,"status":70,"phases":4919,"primaryCompletion":4093,"completion":4093,"start":4920,"enrollment":4921,"conditions":4922,"interventions":4923},"NCT04464707","A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age",[40],"2020-09-24",292,[23],[4808],{"nctId":4925,"briefTitle":4926,"status":70,"phases":4927,"primaryCompletion":4928,"completion":4929,"start":4930,"enrollment":4931,"conditions":4932,"interventions":4933},"NCT02638103","Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine",[40],"2018-06-06","2018-12-08","2016-02-26",1890,[23],[4808],{"nctId":4935,"briefTitle":4936,"status":58,"phases":4937,"primaryCompletion":4938,"completion":4938,"start":4939,"enrollment":4940,"conditions":4941,"interventions":4943},"NCT02964338","A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)",[40],"2018-07-18","2017-01-17",259,[4942],"Chronic Cluster Headache",[4808],{"trials":4945,"activeCount":8},[4946],{"nctId":4947,"briefTitle":4948,"status":70,"phases":4949,"primaryCompletion":4950,"completion":4950,"start":4951,"enrollment":4952,"conditions":4953,"interventions":4955},"NCT04041284","A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder",[41],"2022-08-31","2019-09-13",353,[23,4954],"Major Depressive Disorder",[4808],{"trials":4957,"activeCount":8},[4958],{"nctId":4959,"briefTitle":4960,"status":4961,"phases":4962,"conditions":4963,"interventions":4964},"NCT03539393","Fremanezumab Compassionate Use Program for Pediatric Patients","AVAILABLE",[],[23],[4808],{"intervention":2238,"totalTrials":21,"cells":4966},{"EARLY_PHASE1":4967,"PHASE1":4969,"PHASE2":4971,"PHASE3":4983,"PHASE4":5026,"NA":5028},{"trials":4968,"activeCount":8},[],{"trials":4970,"activeCount":8},[],{"trials":4972,"activeCount":8},[4973],{"nctId":4974,"briefTitle":4975,"status":70,"phases":4976,"primaryCompletion":4977,"completion":4977,"start":4978,"enrollment":4979,"conditions":4980,"interventions":4982},"NCT00977665","Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)",[39],"2011-10","2009-12",174,[4981],"Multiple System Atrophy",[2238],{"trials":4984,"activeCount":8},[4985,4992,4996,5004,5012,5022],{"nctId":4986,"briefTitle":4987,"status":70,"phases":4988,"primaryCompletion":4989,"completion":2233,"start":516,"enrollment":3143,"conditions":4990,"interventions":4991},"NCT00203138","Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease",[40],"2006-11",[17],[2238],{"nctId":2230,"briefTitle":2231,"status":70,"phases":4993,"primaryCompletion":2233,"start":2234,"enrollment":2235,"conditions":4994,"interventions":4995},[40],[17],[2238,2219],{"nctId":4997,"briefTitle":4998,"status":70,"phases":4999,"primaryCompletion":3295,"completion":5000,"start":5001,"enrollment":2235,"conditions":5002,"interventions":5003},"NCT00203164","Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients",[40],"2006-09","2002-05",[17],[2238],{"nctId":5005,"briefTitle":5006,"status":70,"phases":5007,"primaryCompletion":2715,"completion":2715,"start":5008,"enrollment":5009,"conditions":5010,"interventions":5011},"NCT00203125","A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.",[40],"2000-10",55,[17],[2238],{"nctId":5013,"briefTitle":5014,"status":70,"phases":5015,"primaryCompletion":5016,"completion":4292,"start":5017,"enrollment":5018,"conditions":5019,"interventions":5020},"NCT00256204","A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease",[40],"2008-04","2005-11",1174,[17],[5021,5021],"Rasagiline Mesylate",{"nctId":2712,"briefTitle":2713,"status":70,"phases":5023,"primaryCompletion":2715,"completion":2715,"start":2716,"enrollment":2717,"conditions":5024,"interventions":5025},[40],[17],[2238,2701],{"trials":5027,"activeCount":8},[],{"trials":5029,"activeCount":8},[5030,5038],{"nctId":5031,"briefTitle":5032,"status":70,"phases":5033,"primaryCompletion":115,"completion":2399,"start":4978,"enrollment":5034,"conditions":5035,"interventions":5036},"NCT01032486","Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease",[],120,[17],[5037],"Rasagiline mesylate",{"nctId":5039,"briefTitle":5040,"status":70,"phases":5041,"primaryCompletion":1185,"completion":1185,"start":188,"enrollment":5042,"conditions":5043,"interventions":5044},"NCT00936676","ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects",[],684,[17],[2238],{"intervention":294,"totalTrials":1047,"cells":5046},{"EARLY_PHASE1":5047,"PHASE1":5049,"PHASE2":5051,"PHASE3":5057,"PHASE4":5072,"NA":5082},{"trials":5048,"activeCount":8},[],{"trials":5050,"activeCount":8},[],{"trials":5052,"activeCount":8},[5053],{"nctId":999,"briefTitle":1000,"status":70,"phases":5054,"primaryCompletion":311,"completion":311,"start":1002,"enrollment":1003,"conditions":5055,"interventions":5056},[39],[14],[404,974,1006,294],{"trials":5058,"activeCount":8},[5059,5063],{"nctId":2607,"briefTitle":2608,"status":70,"phases":5060,"primaryCompletion":2610,"completion":2610,"start":2611,"enrollment":2612,"conditions":5061,"interventions":5062},[40],[14],[294,2596],{"nctId":5064,"briefTitle":5065,"status":70,"phases":5066,"primaryCompletion":5067,"completion":5067,"start":5068,"enrollment":5069,"conditions":5070,"interventions":5071},"NCT00308685","Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics",[40],"2006-12-04","2006-06-10",95,[14],[294],{"trials":5073,"activeCount":8},[5074,5078],{"nctId":285,"briefTitle":286,"status":70,"phases":5075,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":5076,"interventions":5077},[41],[14],[247,294,295,296],{"nctId":588,"briefTitle":589,"status":70,"phases":5079,"primaryCompletion":591,"completion":591,"start":592,"enrollment":593,"conditions":5080,"interventions":5081},[41],[14],[575,596],{"trials":5083,"activeCount":8},[5084],{"nctId":5085,"briefTitle":5086,"status":70,"phases":5087,"primaryCompletion":115,"completion":115,"start":106,"enrollment":3143,"conditions":5088,"interventions":5091},"NCT01302587","A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)",[],[14,1358,5089,5090],"Emphysema","Chronic Bronchitis",[294],{"intervention":5093,"totalTrials":538,"cells":5094},"Group R+AD Rasagiline + Antidepressant",{"EARLY_PHASE1":5095,"PHASE1":5097,"PHASE2":5099,"PHASE3":5101,"PHASE4":5103,"NA":5105},{"trials":5096,"activeCount":8},[],{"trials":5098,"activeCount":8},[],{"trials":5100,"activeCount":8},[],{"trials":5102,"activeCount":8},[],{"trials":5104,"activeCount":8},[],{"trials":5106,"activeCount":8},[5107],{"nctId":5108,"briefTitle":5109,"status":70,"phases":5110,"primaryCompletion":5111,"completion":198,"start":188,"enrollment":5112,"conditions":5113,"interventions":5115},"NCT00955604","Azilect + Antidepressant Chart Review",[],"2010-03",1500,[5114],"Serotonin Syndrome",[5093,5116,5117],"Group R Rasagiline","Group AD Anti-PD + Antidepressant",{"intervention":5116,"totalTrials":538,"cells":5119},{"EARLY_PHASE1":5120,"PHASE1":5122,"PHASE2":5124,"PHASE3":5126,"PHASE4":5128,"NA":5130},{"trials":5121,"activeCount":8},[],{"trials":5123,"activeCount":8},[],{"trials":5125,"activeCount":8},[],{"trials":5127,"activeCount":8},[],{"trials":5129,"activeCount":8},[],{"trials":5131,"activeCount":8},[5132],{"nctId":5108,"briefTitle":5109,"status":70,"phases":5133,"primaryCompletion":5111,"completion":198,"start":188,"enrollment":5112,"conditions":5134,"interventions":5135},[],[5114],[5093,5116,5117],{"intervention":5117,"totalTrials":538,"cells":5137},{"EARLY_PHASE1":5138,"PHASE1":5140,"PHASE2":5142,"PHASE3":5144,"PHASE4":5146,"NA":5148},{"trials":5139,"activeCount":8},[],{"trials":5141,"activeCount":8},[],{"trials":5143,"activeCount":8},[],{"trials":5145,"activeCount":8},[],{"trials":5147,"activeCount":8},[],{"trials":5149,"activeCount":8},[5150],{"nctId":5108,"briefTitle":5109,"status":70,"phases":5151,"primaryCompletion":5111,"completion":198,"start":188,"enrollment":5112,"conditions":5152,"interventions":5153},[],[5114],[5093,5116,5117],{"intervention":5155,"totalTrials":538,"cells":5156},"Beclomethasone Dipropionate (BDP) Nasal Aerosol",{"EARLY_PHASE1":5157,"PHASE1":5159,"PHASE2":5161,"PHASE3":5163,"PHASE4":5165,"NA":5167},{"trials":5158,"activeCount":8},[],{"trials":5160,"activeCount":8},[],{"trials":5162,"activeCount":8},[],{"trials":5164,"activeCount":8},[],{"trials":5166,"activeCount":8},[],{"trials":5168,"activeCount":8},[5169],{"nctId":5170,"briefTitle":5171,"status":70,"phases":5172,"primaryCompletion":82,"completion":786,"start":3947,"enrollment":5173,"conditions":5174,"interventions":5176},"NCT01632540","Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis",[],824,[5175],"Perennial Allergic Rhinitis (PAR)",[5155]]